ClinicalTrials.gg
CompletedNCT05131477STREAM-ADUpdated Jul 3, 2025Results posted

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

A Phase 2 interventional study of Amlitelimab and Placebo in Eczema and Atopic Dermatitis, sponsored by Kymab Limited. Completed at 103 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Kymab Limited (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Eczema with a site in Poland — 5 open to participants now, 10 under way, 4 of them phase 3. Eczema · Poland.

Enrollment
25th of 72
390 · median 290
Started
2021
with 6 others
Phase 2
24 of 72
3 open now
Registered
37th of 72
by date

Among the 72 studies in Eczema with a site in Poland, this one is the 25th largest by enrollment, is one of 7 that started in 2021, is one of 24 in phase 2, and was the 37th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

5 of the 72 studies in Eczema with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Eczema with a site in Poland, or all of them as a file.
02

Study summary

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.

The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.

03

Conditions studied

  • Eczema
  • Atopic Dermatitis

Keywords

  • KY1005
  • Monoclonal Antibody
  • Atopic Dermatitis
  • Atopic Eczema
  • OX40L
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (18 to \< 75 years of age) with AD as defined by the American Academy of Dermatology Consensus Criteria for 1 year or longer at Baseline.
  • Eczema Area and Severity Index (EASI) of 12 or higher at the Screening Visit and 16 or higher at Baseline.
  • Investigator's Global Assessment (IGA) Scale of 3 or 4 at Baseline.
  • AD involvement of 10% or more of body surface area (BSA) at Baseline.
  • Baseline worst/maximum pruritus Numeric Rating Scale (NRS) of ≥4.
  • Documented history, within 6 months prior to Baseline, of either inadequate response or inadvisability of topical treatments.
  • Must have applied a stable dose of topical bland emollient (simple moisturizer, no additives [e.g., urea]) at least twice daily for a minimum of 7 consecutive days before Baseline.
  • Able to complete patient questionnaires.
  • Able and willing to comply with requested study visits/telephone visits and procedures.
  • Able and willing to provide written .
  • For patients who decide to join the sub-study be able and willing to provide skin biopsies.

Exclusion criteria

Exclusion Criteria:

  • Treatment within specific time windows before the baseline visit for the management of atopic dermatitis such as topical or systemic , biologic or therapies and/or phototherapy.
  • Known history of, or suspected, significant current , including history of invasive opportunistic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Weight \<40 kg or >150 kg at Baseline.
  • Treatment with a live (attenuated) immunization within 12 weeks prior to Baseline.
  • Men and women (of ) unwilling to use and women who are pregnant or breastfeeding.
  • Any or history of malignancies prior to Baseline (except for non-melanoma skin cancer that has been excised and cured for more than 3 years prior to Baseline; in situ cervical carcinoma that has been excised and cured).
  • Positive for (HIV), or at the screening visit.
  • Severe concomitant illness that would in the Investigator's opinion inhibit the patient's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease.
  • In the Investigator's opinion, any laboratory results from the clinical chemistry, hematology or urinalysis tests at the Screening Visit.
  • Concurrent participation in any other clinical study, including non-interventional studies.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    250mg (500mg Loading Dose) KY1005

    Every 4 weeks

    Drug: Amlitelimab

  • Experimental
    250mg (No Loading Dose) KY1005

    Every 4 weeks

    Drug: Amlitelimab

  • Experimental
    125mg KY1005

    Every 4 weeks

    Drug: Amlitelimab

  • Experimental
    62.5mg KY1005

    Every 4 weeks

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Every 4 weeks

    Drug: Placebo

Interventions

  • Pharmaceutical form: Injection solution Route of administration: Subcutaneous

    Also known as: KY1005, SAR445229, A human anti-OX40 ligand monoclonal antibody

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to week 24

  2. Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to week 16 and week 24

  3. Percentage of Participants With a Response of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline ≥ 2 Points (Part 1)

    The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear,1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.

    Time frame: Baseline to week 16 and week 24

  4. Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 1)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to week 16 and week 24

  5. Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 2)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks week 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52

  6. Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24

  7. Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 2,4, 8,12,16, 20 and 24

  8. Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52

  9. Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52

  10. Percentage of Participants With at Least a 50% Reduction From Baseline in EASI (EASI 50) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24

  11. Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline at weeks 2, 4, 8, 12, 16, 20 and 24

  12. Percentage of Participants With at Least a 90% Reduction From Baseline in EASI (EASI 90) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24

  13. Percentage of Participants With a 100% Reduction From Baseline in EASI (EASI 100) (Part 1)

    Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20 and 24

  14. Change in IGA (Investigator Global Assessment) From Baseline to (Week 24) (Part 1)

    The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24

  15. Change in IGA (Investigator Global Assessment) From Baseline (Part 2)

    The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

    Time frame: Baseline to weeks 24, 28, 31, 36, 40, 44, 48 & 52

  16. Percentage of Participants With a Score of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline of ≥ 2 Points (Part 1)

    The IGA is a five-point scale that provides a global clinical assessment of AD (Atopic Dermatitis) severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

    Time frame: Baseline to weeks 2, 4, 8,12,16,20 & 24

  17. Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)

    SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

    Time frame: Baseline to weeks 4, 8, 12, 16, 20 & 24

  18. Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)

    SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

    Time frame: Baseline to week 24, 28, 32, 36, 40, 44, 48 & 52

  19. Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)

    SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

    Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24

  20. Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)

    SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52

  21. Absolute Change in Affected Body Surface Area (BSA) From Baseline (Part 1)

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24

  22. Absolute Change in Affected BSA From Baseline (Part 2)

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52

  23. Percentage Change in Affected BSA From Baseline (Part 1)

    Time frame: Baseline to weeks 2, 4, 8, 12, 16, 20, & 24

  24. Percentage Change in Affected BSA From Baseline (Part 2)

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52

  25. Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)

    POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

    Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24

  26. Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)

    POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

    Time frame: Baseline to weeks 24, 32, 36, 40, 44, 48 & 52

  27. Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)

    POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

    Time frame: Baseline to weeks 4, 8, 12, 16, 20, & 24

  28. Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)

    POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

    Time frame: Baseline to weeks 24, 32, 36, 40. 44, 48, & 52

  29. Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Parts 1)

    DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

    Time frame: Baseline to weeks 2, 8, 16, 20, & 24

  30. Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)

    DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52

  31. Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 1)

    DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

    Time frame: Baseline to weeks 2, 8, 16, 20, & 24

  32. Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)

    DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52

  33. Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)

    ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

    Time frame: Baseline to weeks 16, & 24

  34. Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)

    ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

    Time frame: Baseline to weeks 24, 36 & 52

  35. Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)

    ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

    Time frame: Baseline to weeks 16, & 24

  36. Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)

    ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

    Time frame: Baseline to weeks 24, 36 & 52

  37. Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to weeks 8 16, 20, & 24

  38. Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52

  39. Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to weeks 8, 16, 20, & 24

  40. Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52

  41. Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24

  42. Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52

  43. Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 & 24

  44. Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52

  45. Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 3 With a Baseline Pruritus NRS ≥ 3 From Baseline (Part 1)

    The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24

  46. Incidence Rate of Loss of EASI 50 (Part 2)

    The incidence rate of loss of EASI 50 is calculated for participants who achieved EASI 50 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 50 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 50) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

    Time frame: Week 24 to week 52

  47. Incidence Rate of Loss of EASI 75 (Part 2)

    The incidence rate of loss of EASI 75 is calculated for participants who achieved EASI 75 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 75 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 75) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

    Time frame: Week 24 to week 52

  48. Incidence Rate of Loss of IGA 0/1 (Part 2)

    The incidence rate of loss of IGA 0/1 is calculated for participants who achieved IGA 0/1 at re-randomization (week 24). The incidence rate is computed as the number of participants losing IGA 0/1 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of IGA 0/1) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

    Time frame: Week 24 to week 68

  49. Serum KY1005 Concentration Assessed Throughout the Study (Part 1)

    Time frame: Baseline and at weeks 1, 2, 4, 8, 12, 16, 17, 20, & 24

  50. Serum KY1005 Concentration Assessed Throughout the Study (Part 2)

    Time frame: Baseline and at weeks 24, 25, 28, 32, 36, 40, 44, 48, & 52

  51. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 1)

    Time frame: Baseline through week 24

  52. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 2)

    Time frame: Week 24 through week 68

  53. Percentage of Participants With Treatment-emergent ADA (Part 1)

    Time frame: Baseline through week 24

  54. Percentage of Participants With Treatment-emergent ADA (Part 2)

    Time frame: Baseline through week 68

07

Results

Posted Jul 3, 2025

Participant flow

This study started in December 2021 and ended in February 2024. An individual participant was part of this study for about 1 year and 5 months. The study took place at 100 sites in 12 countries. Up to 350 participants (approximately 70 participants per treatment group) were planned to be enrolled.

PART 1
Participant flow — PART 1
Milestone250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Started7778777979000000000
Randomized and treated7778777878000000000
Re-randomized at week 244740454216000000000
Completed6862696757000000000
Not completed91681222000000000
Withdrew: Withdrawal by subject29628000000000
Withdrew: Physician decision10000000000000
Withdrew: Adverse event35164000000000
Withdrew: Unclassified11004000000000
Withdrew: Randomized and not treated00011000000000
Withdrew: Protocol violation20010000000000
Withdrew: Lack of efficacy01125000000000
PART 2
Participant flow — PART 2
Milestone250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Started0000013341228123373516
Re-randomized and treated0000013341128123273415
Completed0000012311124112872913
Not completed00000131415063
Withdrew: Withdrawal by subject00000020002022
Withdrew: Other00000000110010
Withdrew: Lack of efficacy00000110301020
Withdrew: Unclassified00000000001000
Withdrew: Re-randomized and not treated00000001001011

Outcome measures

PrimaryPercentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to week 16
Reported as:
Least squares mean · percentage of change
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)
percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)-61.5 ± 4.68-56.8 ± 4.59-51.6 ± 4.59-59.6 ± 4.53-29.4 ± 4.76
Statistical analysis
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Ls mean difference: -32.1 · 95% CI -43.9 to -20.3LS Mean Difference
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Ls mean difference: -27.3 · 95% CI -39.1 to -15.6LS Mean Difference
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = 0.0002 · Ls mean difference: -22.2 · 95% CI -34.0 to -10.4LS Mean Difference
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Mean difference (final values): -30.2 · 95% CI -41.9 to -18.5
SecondaryPercentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to week 24
Reported as:
Least squares mean · percentage of change
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1)
percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 24 (Part 1)-64.4 ± 5.17-52.2 ± 5.14-53.7 ± 5.08-54.4 ± 5.09-27.6 ± 5.29
Statistical analysis
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Ls mean difference: -36.8 · 95% CI -49.8 to -23.8LS Mean Difference
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = 0.0002 · Ls mean difference: -24.6 · 95% CI -37.7 to -11.6LS Mean Difference
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Ls mean difference: -26.2 · 95% CI -39.2 to -13.1LS Mean Difference
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · ANCOVA · p = <0.0001 · Ls mean difference: -26.8 · 95% CI -39.7 to -13.9LS Mean Difference
SecondaryPercentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to week 16 and week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) at Week 16 and Week 24 (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 1640.338.542.940.511.4
Week 2454.538.549.440.517.7
Statistical analysis
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = < 0.0001 · Proportion difference: 0.29 · 95% CI 0.16 to 0.42
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = < 0.0001 · Proportion difference: 0.27 · 95% CI 0.14 to 0.40
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.31 · 95% CI 0.18 to 0.44
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.29 · 95% CI 0.16 to 0.42
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.36 · 95% CI 0.23 to 0.5
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0040 · Proportion difference: 0.21 · 95% CI 0.07 to 0.34
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.31 · 95% CI 0.17 to 0.45
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0016 · Proportion difference: 0.23 · 95% CI 0.09 to 0.36
SecondaryPercentage of Participants With a Response of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline ≥ 2 Points (Part 1)

The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear,1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.

Time frame:
Baseline to week 16 and week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline ≥ 2 Points (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 1622.114.119.525.35.1
Week 2445.533.340.329.111.4
Statistical analysis
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0022 · Proportion difference: 0.17 · 95% CI 0.06 to 0.27
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0562 · Proportion difference: 0.09 · 95% CI 0 to 0.18
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0054 · Proportion difference: 0.14 · 95% CI 0.04 to 0.24
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0003 · Proportion difference: 0.2 · 95% CI 0.1 to 0.31
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.34 · 95% CI 0.21 to 0.47
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0008 · Proportion difference: 0.22 · 95% CI 0.1 to 0.34
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 0.29 · 95% CI 0.16 to 0.41
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0046 · Proportion difference: 0.18 · 95% CI 0.06 to 0.3
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 1)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to week 16 and week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 1624.719.220.822.85.1
Week 2431.224.428.627.87.6
Statistical analysis
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0006 · Proportion difference: 0.19 · 95% CI 0.09 to 0.3
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0057 · Proportion difference: 0.14 · 95% CI 0.04 to 0.24
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0038 · Proportion difference: 0.16 · 95% CI 0.05 to 0.26
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0011 · Proportion difference: 0.18 · 95% CI 0.07 to 0.28
  • 250 mg (500 mg LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0002 · Proportion difference: 0.23 · 95% CI 0.11 to 0.35
  • 250 mg (no LD) KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0038 · Proportion difference: 0.17 · 95% CI 0.06 to 0.28
  • 125 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0006 · Proportion difference: 0.21 · 95% CI 0.09 to 0.32
  • 62.5 mg KY1005 (Part 1) vs Placebo (Part 1) · Cochran-Mantel-Haenszel · p = 0.0008 · Proportion difference: 20 · 95% CI 9 to 32
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 2)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks week 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 4 With a Baseline Pruritus of ≥ 4 From Baseline (Part 2)
Percentage of participants250 mg KY1005 Re-Randomized From the LD Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 2453.841.275.035.758.345.571.445.725.0
Week 2553.841.266.739.366.739.457.137.131.3
Week 2653.838.266.732.158.333.371.442.925.0
Week 2761.535.358.328.658.339.471.437.125.0
Week 2861.535.366.735.758.342.457.137.125.0
Week 2969.238.250.025.058.345.557.140.025.0
Week 3061.544.158.325.066.736.442.942.918.8
Week 3161.541.258.325.066.736.442.940.018.8
Week 3261.547.150.025.075.042.471.440.018.8
Week 3361.547.158.328.658.342.471.440.018.8
Week 3461.541.275.021.475.030.342.937.125.0
Week 3561.541.266.721.466.739.471.434.325.0
Week 3661.538.258.321.466.742.471.440.025.0
Week 3753.841.250.028.666.742.471.437.118.8
Week 3853.835.350.025.058.342.471.431.418.8
Week 3953.841.250.025.058.339.471.431.425.0
Week 4053.838.233.325.058.336.428.631.425.0
Week 4161.535.341.728.666.739.457.134.331.3
Week 4253.838.250.028.666.736.442.931.425.0
Week 4353.835.350.028.658.336.442.934.331.3
Week 4461.538.241.721.475.039.442.937.125.0
Week 4561.541.241.721.475.036.442.940.031.3
Week 4653.844.150.028.650.027.342.937.131.3
Week 4746.238.233.328.658.330.342.945.725.0
Week 4838.535.341.728.666.727.357.137.125.0
Week 4938.541.250.035.766.730.357.140.025.0
Week 5038.535.350.032.166.724.257.137.125.0
Week 5130.832.441.728.658.327.342.934.325.0
Week 5246.229.441.725.066.727.357.140.025.0
SecondaryAbsolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Mean · score on a scale
Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)
score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-8.49 ± 10.777-5.27 ± 8.485-6.17 ± 10.071-7.51 ± 8.836-3.98 ± 7.855
Week 4-11.21 ± 10.612-8.38 ± 9.944-10.33 ± 10.861-10.27 ± 10.550-7.20 ± 8.510
Week 8-15.67 ± 11.872-11.93 ± 11.018-13.77 ± 12.964-14.37 ± 10.054-7.64 ± 10.450
Week 12-18.49 ± 12.411-13.84 ± 11.121-16.56 ± 14.062-16.46 ± 11.699-8.76 ± 9.608
Week 16-19.71 ± 12.731-16.31 ± 12.329-15.70 ± 14.226-17.82 ± 11.730-7.47 ± 11.338
Week 20-21.93 ± 14.283-16.46 ± 12.834-16.98 ± 15.321-16.76 ± 12.590-7.91 ± 11.163
Week 24-21.92 ± 14.475-15.72 ± 12.977-16.91 ± 15.085-17.09 ± 13.088-7.52 ± 12.537
SecondaryPercentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 2,4, 8,12,16, 20 and 24
Reported as:
Mean · Percentage of change
Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-27.94 ± 30.032-17.75 ± 38.988-19.09 ± 39.499-26.03 ± 34.462-15.26 ± 34.143
Week 4-36.85 ± 28.901-29.13 ± 42.013-35.10 ± 34.457-35.49 ± 38.786-27.56 ± 31.037
Week 8-50.25 ± 30.666-41.21 ± 41.129-45.96 ± 38.150-51.70 ± 31.046-28.70 ± 38.603
Week 12-59.61 ± 30.717-50.15 ± 36.086-55.23 ± 40.218-57.36 ± 34.275-33.72 ± 35.358
Week 16-62.35 ± 32.322-59.98 ± 37.444-52.50 ± 40.820-61.51 ± 31.663-28.25 ± 41.173
Week 20-67.85 ± 33.135-57.80 ± 38.921-56.29 ± 43.103-57.87 ± 38.977-30.32 ± 40.486
Week 24-68.01 ± 36.052-55.84 ± 40.299-56.72 ± 44.271-57.37 ± 40.225-28.55 ± 44.004
SecondaryAbsolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)
Score on a scale250 mg KY1005 Re-Randomized From the LD Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-29.65 ± 11.278-26.28 ± 13.353-27.60 ± 11.170-18.90 ± 11.932-27.10 ± 12.670-22.45 ± 14.998-25.47 ± 12.209-22.41 ± 12.841-21.47 ± 10.420
Week 28-30.51 ± 12.422-26.34 ± 14.353-25.86 ± 13.128-17.29 ± 12.458-26.37 ± 13.067-22.87 ± 15.667-23.79 ± 10.424-21.75 ± 13.106-21.69 ± 11.918
Week 32-29.08 ± 14.544-24.79 ± 15.775-22.99 ± 15.741-15.38 ± 12.620-27.36 ± 13.383-22.94 ± 14.915-24.94 ± 11.245-20.32 ± 14.189-19.60 ± 10.632
Week 36-28.15 ± 15.138-22.78 ± 17.505-22.27 ± 16.368-14.57 ± 13.550-27.51 ± 13.550-22.99 ± 14.978-24.65 ± 10.801-20.09 ± 15.098-20.20 ± 10.436
Week 40-28.54 ± 15.203-22.30 ± 17.908-22.56 ± 14.949-14.81 ± 13.178-27.96 ± 14.444-20.45 ± 16.659-25.51 ± 11.796-20.80 ± 14.601-20.05 ± 10.596
Week 44-28.43 ± 15.061-22.23 ± 17.487-23.07 ± 15.679-14.49 ± 12.877-27.49 ± 14.324-19.76 ± 16.561-22.34 ± 11.070-20.70 ± 14.343-20.43 ± 11.007
Week 48-22.15 ± 14.876-21.82 ± 17.764-22.24 ± 16.312-13.95 ± 13.596-27.72 ± 14.882-18.34 ± 16.959-23.88 ± 12.517-19.74 ± 15.277-19.99 ± 11.292
Week 52-22.03 ± 14.889-19.59 ± 15.321-22.68 ± 15.418-13.89 ± 13.427-28.08 ± 16.097-17.30 ± 16.752-23.26 ± 11.789-20.81 ± 14.813-20.30 ± 11.526
SecondaryPercentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Reported as:
Mean · Percentage of change
Percentage Change From Baseline in EASI (Eczema Area and Severity Index) (Part 2)
Percentage of change250 mg KY1005 Re-Randomized From the LD Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-91.71 ± 8.539-81.85 ± 31.624-84.20 ± 16.741-72.72 ± 41.299-90.91 ± 10.585-74.56 ± 39.811-85.81 ± 10.212-76.74 ± 30.922-78.51 ± 28.977
Week 28-93.56 ± 8.382-81.47 ± 32.251-79.34 ± 28.091-66.53 ± 43.437-87.78 ± 13.648-74.18 ± 42.104-89.88 ± 6.304-74.54 ± 31.665-76.87 ± 31.377
Week 32-86.08 ± 24.896-76.51 ± 38.401-69.06 ± 38.468-58.78 ± 44.767-91.07 ± 13.744-75.64 ± 41.038-93.76 ± 4.960-68.09 ± 34.850-71.98 ± 33.063
Week 36-86.56 ± 28.656-69.33 ± 43.838-66.64 ± 39.631-56.24 ± 46.469-91.22 ± 13.203-75.77 ± 40.984-93.09 ± 6.000-67.27 ± 40.162-74.93 ± 32.664
Week 40-84.74 ± 28.948-65.65 ± 44.932-68.31 ± 38.024-57.39 ± 47.379-90.68 ± 13.737-64.68 ± 64.041-95.55 ± 5.011-70.11 ± 37.802-74.05 ± 32.343
Week 44-84.46 ± 28.757-66.73 ± 44.328-69.41 ± 38.731-56.30 ± 46.700-90.18 ± 12.912-62.46 ± 63.983-83.57 ± 21.909-69.98 ± 37.145-72.99 ± 33.353
Week 48-71.66 ± 40.416-65.18 ± 44.327-66.61 ± 39.645-53.59 ± 48.780-90.26 ± 12.961-57.47 ± 65.142-88.02 ± 22.234-66.63 ± 40.889-70.92 ± 33.888
Week 52-71.22 ± 40.152-61.78 ± 44.406-68.09 ± 37.719-53.58 ± 48.725-89.09 ± 15.625-54.42 ± 65.177-86.51 ± 22.331-69.76 ± 38.241-72.04 ± 34.827
SecondaryPercentage of Participants With at Least a 50% Reduction From Baseline in EASI (EASI 50) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 50% Reduction From Baseline in EASI (EASI 50) (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 219.515.416.922.813.9
Week 429.921.839.039.224.1
Week 845.538.553.254.427.8
Week 1262.344.961.062.026.6
Week 1663.652.657.165.827.8
Week 2063.651.358.458.225.3
Week 2466.243.655.853.224.1
SecondaryPercentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline at weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 75% Reduction From Baseline in EASI (EASI 75) (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 29.12.62.62.55.1
Week 49.19.011.711.46.3
Week 823.416.727.325.38.9
Week 1233.825.644.243.011.4
Week 1640.338.542.940.511.4
Week 2049.442.348.140.513.9
Week 2454.538.549.440.517.7
SecondaryPercentage of Participants With at Least a 90% Reduction From Baseline in EASI (EASI 90) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 90% Reduction From Baseline in EASI (EASI 90) (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 22.61.301.30
Week 46.51.31.32.50
Week 87.87.79.18.91.3
Week 1210.49.014.312.75.1
Week 1615.614.116.919.03.8
Week 2027.323.124.719.07.6
Week 2437.726.932.524.111.4
SecondaryPercentage of Participants With a 100% Reduction From Baseline in EASI (EASI 100) (Part 1)

Eczema Area and Severity Index-The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD with scores from 0 to 72. Higher scores indicate worse condition.

Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a 100% Reduction From Baseline in EASI (EASI 100) (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 201.3000
Week 42.60000
Week 82.65.11.300
Week 123.92.62.62.50
Week 163.91.32.61.31.3
Week 206.56.43.92.51.3
Week 247.86.49.11.33.8
SecondaryChange in IGA (Investigator Global Assessment) From Baseline to (Week 24) (Part 1)

The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Score on a scale
Change in IGA (Investigator Global Assessment) From Baseline to (Week 24) (Part 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-0.33 ± 0.625-0.21 ± 0.408-0.29 ± 0.540-0.23 ± 0.481-0.18 ± 0.503
Week 4-0.57 ± 0.869-0.38 ± 0.590-0.45 ± 0.620-0.51 ± 0.661-0.31 ± 0.592
Week 8-0.79 ± 0.976-0.74 ± 0.829-0.80 ± 0.900-0.76 ± 0.709-0.32 ± 0.728
Week 12-1.10 ± 1.024-0.87 ± 0.867-1.04 ± 1.013-1.00 ± 0.973-0.36 ± 0.660
Week 16-1.23 ± 0.981-0.99 ± 0.899-0.96 ± 1.033-1.09 ± 0.969-0.43 ± 0.757
Week 20-1.43 ± 1.118-1.17 ± 1.137-1.11 ± 1.120-1.10 ± 0.981-0.45 ± 0.822
Week 24-1.48 ± 1.205-1.16 ± 1.241-1.32 ± 1.265-1.16 ± 1.030-0.49 ± 0.959
SecondaryChange in IGA (Investigator Global Assessment) From Baseline (Part 2)

The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

Time frame:
Baseline to weeks 24, 28, 31, 36, 40, 44, 48 & 52
Reported as:
Mean · Score on a scale
Change in IGA (Investigator Global Assessment) From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-2.31 ± 0.855-1.91 ± 1.026-2.00 ± 0.953-1.82 ± 1.156-2.42 ± 0.793-1.82 ± 1.131-2.00 ± 1.000-1.73 ± 0.911-1.63 ± 1.204
Week 28-2.46 ± 0.967-2.00 ± 1.155-2.17 ± 1.193-1.46 ± 1.138-2.25 ± 0.965-1.74 ± 1.064-1.71 ± 0.951-1.47 ± 0.961-1.71 ± 1.383
Week 32-2.00 ± 1.000-1.82 ± 1.314-1.73 ± 1.348-1.32 ± 1.188-2.33 ± 0.985-1.75 ± 1.078-1.71 ± 0.951-1.41 ± 1.160-1.67 ± 1.234
Week 36-2.08 ± 1.188-1.70 ± 1.380-1.40 ± 1.174-1.29 ± 1.182-2.17 ± 1.115-1.81 ± 1.230-2.00 ± 1.000-1.53 ± 1.344-1.67 ± 1.234
Week 40-2.08 ± 1.115-1.71 ± 1.395-1.64 ± 1.286-1.29 ± 1.301-2.36 ± 1.120-1.75 ± 1.164-1.86 ± 1.215-1.58 ± 1.311-1.53 ± 1.302
Week 44-2.00 ± 1.155-1.69 ± 1.447-1.73 ± 1.348-1.32 ± 1.335-2.08 ± 1.084-1.63 ± 1.070-1.71 ± 1.113-1.58 ± 1.259-1.64 ± 1.393
Week 48-1.69 ± 1.182-1.69 ± 1.469-1.60 ± 1.350-1.36 ± 1.367-2.08 ± 1.240-1.50 ± 1.137-2.00 ± 1.414-1.63 ± 1.351-1.71 ± 1.590
Week 52-1.77 ± 1.301-1.55 ± 1.434-1.64 ± 1.286-1.36 ± 1.420-2.18 ± 1.401-1.48 ± 1.214-2.00 ± 1.155-1.65 ± 1.305-1.79 ± 1.672
SecondaryPercentage of Participants With a Score of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline of ≥ 2 Points (Part 1)

The IGA is a five-point scale that provides a global clinical assessment of AD (Atopic Dermatitis) severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe AD

Time frame:
Baseline to weeks 2, 4, 8,12,16,20 & 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Score of IGA (Investigator Global Assessment) 0 or 1 and a Reduction From Baseline of ≥ 2 Points (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 21.30001.3
Week 45.21.31.32.52.5
Week 89.19.013.05.15.1
Week 1216.912.819.519.03.8
Week 1622.114.119.525.35.1
Week 2033.825.627.321.58.9
Week 2445.533.340.329.111.4
SecondaryAbsolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)

SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

Time frame:
Baseline to weeks 4, 8, 12, 16, 20 & 24
Reported as:
Mean · Score on a scale
Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 4-15.30 ± 16.517-12.27 ± 13.455-15.89 ± 14.865-14.43 ± 13.691-11.13 ± 14.243
Week 8-22.39 ± 19.368-19.61 ± 17.527-21.49 ± 19.200-21.42 ± 16.956-12.50 ± 16.584
Week 12-27.80 ± 19.621-22.31 ± 17.936-27.72 ± 20.084-26.45 ± 19.649-13.97 ± 16.898
Week 16-30.12 ± 20.086-25.07 ± 20.233-26.28 ± 21.258-28.15 ± 19.831-13.85 ± 18.123
Week 20-34.89 ± 22.369-28.04 ± 22.472-29.80 ± 23.594-26.71 ± 21.056-13.91 ± 19.325
Week 24-36.19 ± 24.605-27.28 ± 22.937-29.96 ± 25.735-28.48 ± 21.793-15.08 ± 22.739
SecondaryAbsolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)

SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

Time frame:
Baseline to week 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Score on a scale
Absolute Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-52.22 ± 14.314-44.25 ± 21.373-42.44 ± 21.879-36.77 ± 21.919-49.87 ± 13.012-41.65 ± 24.173-45.20 ± 18.017-38.45 ± 22.077-40.54 ± 23.584
Week 28-54.19 ± 18.525-44.30 ± 23.737-43.38 ± 24.261-33.40 ± 23.845-47.15 ± 16.401-43.95 ± 24.475-41.17 ± 19.190-37.46 ± 23.843-42.98 ± 24.770
Week 32-51.19 ± 23.086-41.55 ± 25.962-37.58 ± 27.000-28.31 ± 23.318-50.76 ± 16.285-44.04 ± 22.541-40.76 ± 17.685-36.72 ± 25.421-37.81 ± 25.964
Week 36-49.68 ± 25.709-38.72 ± 27.164-33.91 ± 26.686-27.91 ± 24.154-52.12 ± 19.167-45.28 ± 23.438-40.09 ± 16.767-37.15 ± 27.483-39.35 ± 25.340
Week 40-49.88 ± 26.342-38.96 ± 29.090-36.05 ± 27.550-30.05 ± 26.602-52.42 ± 19.560-42.93 ± 24.694-45.31 ± 22.710-37.75 ± 27.127-36.74 ± 25.865
Week 44-47.38 ± 26.194-38.61 ± 28.602-37.95 ± 28.362-29.98 ± 26.387-51.14 ± 20.299-40.96 ± 24.470-36.39 ± 21.651-36.83 ± 27.061-37.47 ± 27.887
Week 48-39.75 ± 25.447-38.18 ± 29.948-35.13 ± 27.409-29.71 ± 28.021-52.40 ± 22.250-38.38 ± 24.940-43.80 ± 27.380-37.64 ± 28.543-38.10 ± 28.181
Week 52-40.26 ± 26.751-34.69 ± 28.925-35.04 ± 27.120-29.26 ± 27.488-50.26 ± 26.772-37.07 ± 25.763-42.26 ± 25.861-38.41 ± 26.915-39.94 ± 29.182
SecondaryPercentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)

SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

Time frame:
Baseline to weeks 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Percentage of change
Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 4-22.02 ± 22.050-18.52 ± 20.315-22.76 ± 20.903-21.42 ± 21.101-16.67 ± 21.045
Week 8-31.84 ± 24.549-30.00 ± 28.050-30.47 ± 26.260-32.07 ± 23.600-18.27 ± 23.875
Week 12-40.32 ± 25.145-33.64 ± 26.502-39.38 ± 27.228-39.22 ± 26.807-20.70 ± 24.587
Week 16-43.25 ± 26.555-37.18 ± 28.395-37.33 ± 29.071-41.44 ± 26.134-20.87 ± 26.791
Week 20-49.92 ± 28.279-42.07 ± 32.179-42.30 ± 32.422-39.05 ± 28.347-20.88 ± 28.527
Week 24-57.87 ± 32.609-41.04 ± 34.212-42.58 ± 35.812-41.49 ± 29.263-22.21 ± 33.233
SecondaryPercentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)

SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Percentage of change
Percentage Change in SCORAD (SCORing Atopic Dermatitis) Index From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-76.47 ± 11.581-63.86 ± 27.005-60.09 ± 26.373-57.73 ± 34.302-72.55 ± 15.422-58.96 ± 31.260-66.12 ± 19.532-55.75 ± 26.945-60.13 ± 33.848
Week 28-78.39 ± 16.236-63.35 ± 28.625-62.58 ± 32.229-52.12 ± 35.950-68.39 ± 21.143-61.69 ± 32.214-64.22 ± 18.649-53.98 ± 29.707-62.81 ± 36.300
Week 32-72.44 ± 25.786-59.37 ± 33.889-53.42 ± 34.955-44.49 ± 35.890-74.03 ± 21.589-62.38 ± 31.104-64.07 ± 16.853-52.47 ± 31.788-56.11 ± 38.003
Week 36-71.50 ± 31.364-55.13 ± 35.598-49.88 ± 36.111-43.78 ± 36.278-75.08 ± 21.563-63.79 ± 31.710-64.24 ± 20.730-53.95 ± 35.053-58.72 ± 36.827
Week 40-71.43 ± 31.643-54.79 ± 38.533-51.85 ± 37.053-46.81 ± 39.055-74.34 ± 22.474-61.12 ± 34.217-70.27 ± 22.037-54.56 ± 34.785-54.24 ± 36.614
Week 44-67.26 ± 31.749-54.96 ± 38.272-54.10 ± 37.251-46.95 ± 39.736-73.34 ± 22.409-57.94 ± 33.953-58.19 ± 33.365-52.89 ± 34.032-55.26 ± 39.204
Week 48-59.99 ± 35.979-53.71 ± 39.548-51.66 ± 37.347-45.48 ± 41.426-74.37 ± 23.066-54.55 ± 34.719-67.92 ± 35.766-54.29 ± 35.851-56.30 ± 39.696
Week 52-60.41 ± 36.686-49.90 ± 40.104-49.68 ± 35.129-44.93 ± 40.527-69.62 ± 29.104-52.47 ± 35.396-65.97 ± 34.709-56.19 ± 34.460-58.86 ± 40.701
SecondaryAbsolute Change in Affected Body Surface Area (BSA) From Baseline (Part 1)
Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Percentage of body surface area
Absolute Change in Affected Body Surface Area (BSA) From Baseline (Part 1)
Percentage of body surface area250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-4.50 ± 10.610-5.61 ± 10.165-9.08 ± 15.999-7.41 ± 12.588-4.84 ± 9.113
Week 4-12.83 ± 15.922-10.16 ± 12.917-13.34 ± 17.347-12.51 ± 16.318-9.67 ± 16.941
Week 8-19.37 ± 18.857-15.77 ± 17.004-17.55 ± 21.064-19.11 ± 18.253-10.00 ± 17.375
Week 12-24.13 ± 18.097-19.54 ± 19.578-21.94 ± 22.715-24.14 ± 19.903-11.46 ± 17.035
Week 16-26.91 ± 20.286-22.71 ± 21.966-21.74 ± 24.799-26.04 ± 20.403-8.87 ± 16.956
Week 20-30.25 ± 21.850-23.33 ± 22.600-24.35 ± 26.238-24.63 ± 21.263-11.04 ± 19.653
Week 24-31.35 ± 22.434-21.82 ± 21.882-22.66 ± 27.317-25.77 ± 22.085-10.45 ± 20.837
SecondaryAbsolute Change in Affected BSA From Baseline (Part 2)
Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Percentage of body surface area
Absolute Change in Affected BSA From Baseline (Part 2)
Percentage of body surface area250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-46.92 ± 22.009-37.94 ± 18.723-37.17 ± 17.994-28.14 ± 21.790-41.17 ± 22.982-33.81 ± 26.454-40.60 ± 26.006-34.30 ± 19.787-32.06 ± 22.831
Week 28-48.69 ± 23.329-38.68 ± 20.582-35.92 ± 20.804-25.54 ± 22.718-40.00 ± 23.394-35.61 ± 25.720-37.14 ± 23.801-33.62 ± 19.692-36.00 ± 24.553
Week 32-47.15 ± 25.271-36.62 ± 23.049-29.64 ± 25.590-23.21 ± 23.710-42.08 ± 22.685-35.94 ± 26.193-38.00 ± 23.847-32.13 ± 21.515-30.07 ± 22.861
Week 36-46.00 ± 26.242-33.61 ± 24.187-28.30 ± 26.437-22.21 ± 23.857-41.67 ± 23.051-35.75 ± 25.664-37.86 ± 24.674-30.91 ± 24.288-31.27 ± 24.391
Week 40-46.62 ± 26.314-32.94 ± 24.589-29.18 ± 24.774-22.57 ± 23.841-41.45 ± 23.729-33.41 ± 22.649-39.57 ± 24.758-32.00 ± 23.697-31.27 ± 24.566
Week 44-47.23 ± 26.540-33.22 ± 24.143-29.73 ± 25.503-22.21 ± 23.706-42.17 ± 25.283-31.91 ± 22.069-34.43 ± 25.172-32.23 ± 23.250-27.43 ± 20.478
Week 48-35.69 ± 26.183-32.72 ± 25.358-28.30 ± 26.378-21.50 ± 24.053-42.92 ± 25.336-30.53 ± 23.544-36.43 ± 21.141-31.13 ± 26.208-26.93 ± 20.775
Week 52-35.54 ± 26.384-29.48 ± 22.232-29.55 ± 25.359-21.46 ± 23.562-45.09 ± 25.770-29.66 ± 23.818-34.71 ± 18.688-33.33 ± 22.702-27.21 ± 20.955
SecondaryPercentage Change in Affected BSA From Baseline (Part 1)
Time frame:
Baseline to weeks 2, 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Percentage change
Percentage Change in Affected BSA From Baseline (Part 1)
Percentage change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-10.11 ± 24.013-12.23 ± 26.053-19.43 ± 30.139-15.06 ± 37.312-11.45 ± 22.767
Week 4-26.45 ± 28.733-23.44 ± 28.941-29.46 ± 32.934-28.84 ± 38.412-20.92 ± 38.260
Week 8-39.12 ± 31.915-36.01 ± 35.268-37.60 ± 36.988-42.84 ± 33.931-21.24 ± 40.914
Week 12-49.88 ± 29.737-43.68 ± 38.140-47.04 ± 40.519-52.16 ± 35.736-26.56 ± 36.705
Week 16-54.58 ± 32.206-49.44 ± 40.861-46.35 ± 43.511-56.36 ± 35.593-22.37 ± 40.483
Week 20-59.75 ± 33.804-51.07 ± 42.023-50.36 ± 45.871-53.55 ± 42.762-25.46 ± 42.034
Week 24-63.02 ± 36.184-49.42 ± 43.012-48.11 ± 48.748-52.94 ± 44.872-23.76 ± 44.394
SecondaryPercentage Change in Affected BSA From Baseline (Part 2)
Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Percentage change
Percentage Change in Affected BSA From Baseline (Part 2)
Percentage change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-88.09 ± 12.983-78.75 ± 27.966-80.67 ± 27.843-67.85 ± 39.902-85.29 ± 19.008-71.05 ± 39.900-80.52 ± 14.717-74.02 ± 31.419-72.91 ± 34.317
Week 28-90.51 ± 10.816-79.51 ± 29.501-76.55 ± 35.680-62.09 ± 42.748-81.75 ± 24.996-73.28 ± 40.454-88.57 ± 5.800-72.98 ± 30.947-75.14 ± 37.955
Week 32-83.58 ± 23.940-75.09 ± 36.907-65.07 ± 49.743-55.89 ± 45.768-86.34 ± 18.724-74.61 ± 40.429-90.31 ± 10.263-66.90 ± 35.357-69.74 ± 38.644
Week 36-81.56 ± 27.924-68.81 ± 40.261-61.93 ± 51.222-53.48 ± 45.933-85.33 ± 18.348-74.73 ± 40.570-89.70 ± 10.552-63.85 ± 46.152-72.34 ± 39.621
Week 40-82.62 ± 28.019-66.33 ± 41.876-64.54 ± 49.422-54.92 ± 47.035-86.81 ± 17.237-72.10 ± 41.016-94.09 ± 5.083-66.00 ± 43.207-72.08 ± 39.691
Week 44-83.52 ± 28.118-66.91 ± 41.122-65.39 ± 49.945-53.82 ± 46.414-84.47 ± 24.104-69.38 ± 41.133-81.11 ± 19.107-66.54 ± 41.241-70.30 ± 40.560
Week 48-69.37 ± 40.195-64.74 ± 42.092-62.01 ± 51.359-52.52 ± 47.479-85.70 ± 19.040-64.73 ± 42.700-87.79 ± 16.209-62.58 ± 48.827-68.01 ± 40.428
Week 52-68.90 ± 40.301-61.59 ± 42.339-64.90 ± 49.605-52.82 ± 47.733-89.06 ± 14.176-62.25 ± 42.451-85.46 ± 16.921-68.75 ± 39.935-68.78 ± 41.236
SecondaryAbsolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)

POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

Time frame:
Baseline to weeks 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Score on a scale
Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 4-4.40 ± 6.403-4.01 ± 6.287-5.42 ± 6.498-4.08 ± 5.448-2.32 ± 5.910
Week 8-7.03 ± 6.869-5.13 ± 7.093-5.70 ± 6.943-6.75 ± 6.646-2.13 ± 6.400
Week 12-7.87 ± 7.286-6.50 ± 7.229-7.29 ± 7.216-7.36 ± 7.460-2.26 ± 6.088
Week 16-8.28 ± 7.286-7.23 ± 7.744-7.19 ± 7.720-7.32 ± 7.017-2.37 ± 6.867
Week 20-9.39 ± 7.577-7.13 ± 8.662-8.10 ± 8.150-7.39 ± 7.721-2.33 ± 6.821
Week 24-9.96 ± 7.888-7.21 ± 8.213-7.86 ± 8.572-7.64 ± 7.011-2.19 ± 7.310
SecondaryAbsolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)

POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

Time frame:
Baseline to weeks 24, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Score on a scale
Absolute Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-15.31 ± 6.061-11.97 ± 6.410-11.58 ± 8.586-9.25 ± 8.347-11.75 ± 7.086-10.42 ± 7.580-14.00 ± 6.205-9.45 ± 7.155-8.75 ± 7.197
Week 32-14.69 ± 8.499-10.23 ± 8.320-11.91 ± 8.240-6.79 ± 8.875-12.83 ± 7.082-11.32 ± 8.113-11.29 ± 10.323-9.42 ± 7.784-7.62 ± 8.856
Week 36-13.23 ± 8.738-9.91 ± 8.129-11.90 ± 7.264-7.00 ± 8.932-13.00 ± 7.019-11.75 ± 8.370-12.57 ± 9.502-8.66 ± 7.790-7.93 ± 7.966
Week 40-13.92 ± 8.411-9.10 ± 8.715-11.00 ± 6.633-7.82 ± 9.302-11.73 ± 8.162-11.88 ± 8.698-11.29 ± 8.995-8.81 ± 8.300-7.50 ± 7.714
Week 44-13.31 ± 8.460-9.81 ± 8.920-10.45 ± 6.699-6.50 ± 8.804-11.92 ± 8.262-10.19 ± 8.361-7.86 ± 7.515-8.71 ± 8.158-7.93 ± 7.908
Week 48-11.69 ± 9.861-10.39 ± 8.519-11.50 ± 6.916-7.50 ± 9.268-11.75 ± 9.836-10.33 ± 8.125-9.57 ± 9.126-9.90 ± 8.660-7.50 ± 8.438
Week 52-11.85 ± 10.148-9.13 ± 8.320-11.36 ± 6.889-6.82 ± 9.318-10.64 ± 10.053-8.55 ± 8.240-10.00 ± 9.452-8.58 ± 9.164-8.50 ± 9.146
SecondaryPercentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)

POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

Time frame:
Baseline to weeks 4, 8, 12, 16, 20, & 24
Reported as:
Mean · Percentage of change
Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 4-20.81 ± 34.179-21.02 ± 31.360-22.77 ± 30.783-17.94 ± 30.152-8.99 ± 39.554
Week 8-33.06 ± 41.272-26.52 ± 33.397-26.62 ± 34.946-34.60 ± 31.584-6.28 ± 42.851
Week 12-36.22 ± 43.169-32.42 ± 32.145-33.33 ± 33.732-34.61 ± 34.275-8.04 ± 41.445
Week 16-37.08 ± 52.391-34.71 ± 34.574-32.78 ± 36.449-35.49 ± 32.862-8.12 ± 45.515
Week 20-44.03 ± 38.850-34.23 ± 38.938-37.38 ± 38.448-35.37 ± 36.589-8.32 ± 44.942
Week 24-44.69 ± 61.808-33.91 ± 48.273-36.65 ± 40.947-36.81 ± 34.444-6.98 ± 49.837
SecondaryPercentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)

POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity

Time frame:
Baseline to weeks 24, 32, 36, 40. 44, 48, & 52
Reported as:
Mean · Percentage of change
Percentage Change in Patient Oriented Eczema Measure (POEM) From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-72.61 ± 19.898-61.00 ± 30.657-54.05 ± 38.147-46.08 ± 37.356-60.03 ± 30.545-51.61 ± 35.438-64.00 ± 20.049-45.63 ± 34.579-47.92 ± 40.572
Week 32-64.90 ± 38.029-50.03 ± 44.543-56.00 ± 35.875-30.61 ± 39.689-64.21 ± 28.981-55.82 ± 36.229-47.30 ± 57.463-46.42 ± 38.011-43.95 ± 50.962
Week 36-60.09 ± 40.508-48.61 ± 43.883-57.09 ± 34.068-33.73 ± 38.724-66.78 ± 27.084-57.38 ± 37.436-57.54 ± 59.987-43.35 ± 40.000-44.58 ± 45.387
Week 40-62.85 ± 38.659-44.35 ± 45.524-54.47 ± 35.815-37.89 ± 40.032-58.98 ± 33.289-58.12 ± 38.754-49.79 ± 55.862-43.75 ± 40.933-42.88 ± 45.567
Week 44-60.83 ± 40.648-48.48 ± 47.524-52.24 ± 36.218-30.25 ± 43.110-59.17 ± 35.572-50.10 ± 37.814-36.09 ± 53.637-43.16 ± 39.688-46.19 ± 46.429
Week 48-54.56 ± 46.380-51.53 ± 44.857-55.93 ± 35.043-35.37 ± 42.309-58.18 ± 46.077-51.56 ± 39.299-44.04 ± 58.904-50.45 ± 41.809-43.48 ± 48.292
Week 52-54.68 ± 45.987-44.51 ± 43.725-54.47 ± 34.319-29.38 ± 46.373-52.64 ± 47.556-43.45 ± 42.459-48.82 ± 63.478-43.01 ± 45.577-47.62 ± 50.785
SecondaryAbsolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Parts 1)

DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

Time frame:
Baseline to weeks 2, 8, 16, 20, & 24
Reported as:
Mean · Score on a scale
Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Parts 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-3.63 ± 4.992-2.82 ± 4.850-3.32 ± 5.745-3.40 ± 5.131-2.09 ± 4.710
Week 8-6.13 ± 6.164-5.59 ± 5.553-5.08 ± 7.252-7.13 ± 5.954-2.43 ± 5.466
Week 16-7.79 ± 6.832-6.25 ± 6.246-6.47 ± 7.835-7.76 ± 6.265-2.35 ± 6.069
Week 20-7.89 ± 6.848-6.42 ± 6.833-6.97 ± 8.512-7.31 ± 7.132-2.39 ± 6.391
Week 24-8.33 ± 7.036-6.54 ± 6.384-6.74 ± 8.681-7.69 ± 7.230-2.30 ± 6.406
SecondaryAbsolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)

DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Reported as:
Mean · Score on a scale
Absolute Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-12.54 ± 6.703-9.00 ± 6.290-9.08 ± 6.487-7.57 ± 7.295-11.42 ± 7.115-8.26 ± 9.338-15.40 ± 8.562-9.67 ± 7.712-6.44 ± 7.420
Week 28-12.62 ± 8.191-9.52 ± 6.929-9.83 ± 6.658-7.21 ± 6.488-11.33 ± 7.832-8.45 ± 9.705-12.29 ± 9.232-9.68 ± 8.029-5.77 ± 8.633
Week 32-12.38 ± 8.272-8.00 ± 7.612-8.55 ± 8.238-5.75 ± 7.183-12.25 ± 7.700-8.50 ± 9.629-13.14 ± 8.050-9.13 ± 7.906-5.47 ± 7.963
Week 36-11.85 ± 8.122-7.72 ± 7.985-7.90 ± 6.903-6.18 ± 7.222-12.58 ± 7.716-8.84 ± 9.893-14.00 ± 8.446-8.53 ± 7.927-5.93 ± 7.839
Week 40-12.23 ± 7.715-7.07 ± 8.073-7.18 ± 5.456-6.21 ± 7.279-11.27 ± 7.976-8.06 ± 9.844-14.57 ± 7.569-8.23 ± 8.281-5.36 ± 8.308
Week 44-11.38 ± 8.109-7.19 ± 7.943-8.18 ± 6.258-5.68 ± 7.029-12.08 ± 8.426-6.88 ± 9.587-10.29 ± 7.889-8.26 ± 8.058-5.93 ± 6.889
Week 48-9.92 ± 6.800-7.29 ± 8.022-8.40 ± 7.516-6.21 ± 7.218-11.92 ± 8.229-6.83 ± 9.322-11.29 ± 6.237-7.93 ± 7.891-6.79 ± 7.040
Week 52-9.08 ± 6.652-6.83 ± 7.852-8.09 ± 7.077-5.93 ± 7.383-12.55 ± 9.136-6.41 ± 9.428-11.57 ± 6.705-8.10 ± 7.752-6.64 ± 6.902
SecondaryPercentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 1)

DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

Time frame:
Baseline to weeks 2, 8, 16, 20, & 24
Reported as:
Mean · Percentage of change
Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 2-22.68 ± 31.305-11.95 ± 47.921-16.80 ± 41.680-22.73 ± 32.711-10.30 ± 37.999
Week 8-36.87 ± 36.954-36.14 ± 41.176-27.54 ± 59.199-45.85 ± 32.198-13.12 ± 42.775
Week 16-46.69 ± 40.563-41.27 ± 43.616-34.02 ± 62.565-48.96 ± 29.801-11.35 ± 51.739
Week 20-47.48 ± 40.616-42.90 ± 46.336-35.79 ± 67.398-44.33 ± 36.816-12.08 ± 49.973
Week 24-51.84 ± 41.442-42.36 ± 45.550-33.28 ± 72.816-45.63 ± 33.860-11.91 ± 55.694
SecondaryPercentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)

DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48, & 52
Reported as:
Mean · Percentage of change
Percentage Change in Dermatology Life Quality Index (DLQI) From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-75.53 ± 26.705-61.64 ± 35.809-64.74 ± 31.091-44.26 ± 57.217-72.47 ± 27.818-47.08 ± 82.439-70.77 ± 27.653-55.36 ± 33.443-48.30 ± 57.726
Week 28-72.50 ± 37.184-62.65 ± 43.216-71.77 ± 29.970-44.81 ± 56.575-70.02 ± 28.760-48.86 ± 83.936-65.28 ± 26.807-55.62 ± 34.382-41.13 ± 80.192
Week 32-68.19 ± 38.039-48.69 ± 56.833-61.68 ± 42.315-31.65 ± 55.087-77.14 ± 26.277-50.15 ± 83.141-72.98 ± 17.074-52.99 ± 36.735-41.18 ± 68.097
Week 36-65.76 ± 35.792-48.12 ± 56.610-60.50 ± 41.018-35.86 ± 58.071-79.13 ± 24.980-52.16 ± 84.141-78.26 ± 23.932-49.48 ± 43.137-45.04 ± 65.630
Week 40-69.26 ± 34.172-44.78 ± 59.798-58.29 ± 42.112-36.52 ± 58.909-72.31 ± 27.268-46.41 ± 84.277-83.18 ± 16.284-49.75 ± 42.024-38.69 ± 80.196
Week 44-63.03 ± 41.237-45.33 ± 60.470-63.04 ± 42.005-33.25 ± 58.480-76.32 ± 31.166-39.27 ± 83.804-60.44 ± 28.925-49.15 ± 43.228-48.21 ± 48.871
Week 48-59.02 ± 36.676-45.68 ± 59.933-63.97 ± 43.622-35.98 ± 57.915-73.10 ± 28.704-40.20 ± 84.240-70.04 ± 26.437-50.82 ± 41.018-57.92 ± 45.339
Week 52-53.62 ± 36.496-43.64 ± 56.804-61.04 ± 42.716-33.21 ± 59.514-72.35 ± 33.768-35.27 ± 85.953-71.56 ± 28.287-49.24 ± 43.003-57.12 ± 44.899
SecondaryAbsolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)

ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

Time frame:
Baseline to weeks 16, & 24
Reported as:
Mean · Score on a scale
Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 16-6.70 ± 5.813-5.41 ± 6.054-6.22 ± 6.272-6.61 ± 5.804-2.50 ± 4.589
Week 24-7.35 ± 6.695-5.80 ± 6.187-6.70 ± 6.566-6.66 ± 5.868-1.90 ± 5.046
SecondaryAbsolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)

ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

Time frame:
Baseline to weeks 24, 36 & 52
Reported as:
Mean · Score on a scale
Absolute Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-11.23 ± 6.071-8.64 ± 5.927-9.83 ± 6.506-7.44 ± 5.673-9.83 ± 5.132-8.42 ± 6.386-12.60 ± 6.986-8.29 ± 5.996-6.25 ± 6.083
Week 36-11.46 ± 5.681-8.13 ± 6.463-8.20 ± 6.143-7.78 ± 6.123-10.33 ± 5.483-9.26 ± 6.875-10.71 ± 6.550-8.03 ± 6.385-6.38 ± 6.063
Week 52-11.31 ± 4.768-8.30 ± 5.706-8.82 ± 6.809-7.44 ± 6.594-10.45 ± 5.989-6.48 ± 6.539-9.71 ± 4.751-8.34 ± 6.893-7.14 ± 6.125
SecondaryPercentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)

ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

Time frame:
Baseline to weeks 16, & 24
Reported as:
Mean · Percentage of change
Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 16-40.56 ± 37.340-33.42 ± 34.745-36.42 ± 37.103-38.72 ± 30.762-17.04 ± 32.553
Week 24-45.18 ± 42.438-36.20 ± 41.363-40.45 ± 40.708-39.35 ± 31.799-12.31 ± 37.504
SecondaryPercentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)

ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control

Time frame:
Baseline to weeks 24, 36 & 52
Reported as:
Mean · Percentage of change
Percentage Change in Atopic Dermatitis Control Tool (ADCT) From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-66.75 ± 32.632-57.08 ± 37.656-56.01 ± 36.112-49.97 ± 34.078-65.46 ± 26.823-53.10 ± 40.207-63.92 ± 29.784-50.66 ± 33.458-44.95 ± 45.331
Week 36-69.01 ± 29.493-50.38 ± 42.649-50.01 ± 37.199-50.87 ± 33.197-69.73 ± 28.925-58.44 ± 43.340-62.63 ± 23.130-48.59 ± 38.274-49.42 ± 45.902
Week 52-69.93 ± 26.250-54.77 ± 34.128-52.75 ± 41.167-47.15 ± 39.681-67.84 ± 32.469-41.39 ± 43.875-64.19 ± 28.274-50.29 ± 41.341-53.35 ± 47.196
SecondaryAbsolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)

The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

Time frame:
Baseline to weeks 8 16, 20, & 24
Reported as:
Mean · Score on a scale
Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)
Score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 8-2.20 ± 4.639-2.07 ± 6.194-2.35 ± 5.641-3.29 ± 5.132-0.97 ± 3.940
Week 16-2.67 ± 5.761-2.53 ± 6.510-3.04 ± 6.292-3.74 ± 6.401-0.57 ± 5.088
Week 20-2.52 ± 7.254-2.35 ± 7.326-3.38 ± 6.787-4.24 ± 5.873-0.66 ± 4.176
Week 24-2.96 ± 7.550-2.30 ± 6.880-2.83 ± 6.818-4.00 ± 6.802-0.97 ± 4.196
SecondaryAbsolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)

The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · score on a scale
Absolute Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)
score on a scale250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-4.54 ± 8.482-1.73 ± 7.434-5.58 ± 10.184-2.81 ± 6.822-3.67 ± 6.998-4.42 ± 7.890-8.20 ± 6.340-4.03 ± 6.710-0.38 ± 4.660
Week 28-3.54 ± 7.965-2.52 ± 6.205-6.50 ± 11.430-2.70 ± 6.916-4.33 ± 7.679-4.97 ± 8.428-7.29 ± 5.251-5.26 ± 7.0340.38 ± 4.753
Week 32-3.38 ± 8.893-1.24 ± 6.996-4.09 ± 9.027-2.74 ± 7.593-4.42 ± 7.242-5.66 ± 8.280-6.86 ± 5.460-3.97 ± 6.483-0.20 ± 4.491
Week 36-1.85 ± 9.754-1.22 ± 8.015-3.80 ± 10.497-2.52 ± 5.833-4.42 ± 6.999-5.50 ± 8.828-7.14 ± 4.880-3.75 ± 7.8780.29 ± 4.250
Week 40-2.92 ± 8.864-1.40 ± 6.966-3.09 ± 10.222-2.70 ± 6.151-3.55 ± 7.594-5.16 ± 8.674-7.43 ± 5.563-3.29 ± 5.5930.50 ± 5.125
Week 44-2.69 ± 8.873-0.29 ± 6.963-3.45 ± 10.511-3.07 ± 5.313-4.25 ± 7.225-4.56 ± 8.879-5.43 ± 5.192-3.71 ± 7.408-0.21 ± 4.318
Week 48-3.08 ± 8.883-0.68 ± 7.078-4.40 ± 10.024-2.85 ± 5.559-3.33 ± 7.797-5.23 ± 8.724-7.43 ± 5.412-4.17 ± 7.269-1.00 ± 4.852
Week 52-2.46 ± 9.162-0.80 ± 7.092-2.55 ± 8.359-3.00 ± 5.877-4.18 ± 7.167-4.59 ± 8.454-7.29 ± 5.794-3.13 ± 8.082-0.64 ± 5.719
SecondaryPercentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)

The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

Time frame:
Baseline to weeks 8, 16, 20, & 24
Reported as:
Mean · Percentage of change
Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 8-18.40 ± 46.151-11.76 ± 48.829-10.22 ± 56.395-13.15 ± 69.427-0.66 ± 77.969
Week 16-18.12 ± 56.175-11.72 ± 54.678-15.84 ± 54.001-17.47 ± 94.3462.82 ± 101.930
Week 20-20.15 ± 65.506-7.39 ± 62.693-17.62 ± 59.518-25.97 ± 83.249-5.02 ± 78.180
Week 24-13.22 ± 97.953-8.67 ± 60.563-17.75 ± 52.049-12.07 ± 120.061-8.17 ± 77.872
SecondaryPercentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)

The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

Time frame:
Baseline to weeks 24, 28, 32, 36, 40, 44, 48 & 52
Reported as:
Mean · Percentage of change
Percentage Change in Hospital Anxiety and Depression Scale (HADS) From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-28.01 ± 54.369-17.89 ± 76.693-34.27 ± 48.841-13.63 ± 65.697-20.28 ± 49.825-32.24 ± 65.070-46.94 ± 22.063-22.38 ± 58.898-32.55 ± 66.184
Week 28-18.57 ± 53.870-22.56 ± 67.645-30.97 ± 51.945-17.92 ± 53.0984.22 ± 96.782-30.52 ± 66.305-49.58 ± 31.509-33.17 ± 41.412-38.39 ± 77.030
Week 32-19.06 ± 60.844-14.02 ± 82.893-29.10 ± 52.035-20.31 ± 63.189-11.36 ± 87.084-43.96 ± 68.306-42.56 ± 27.759-32.62 ± 49.764-38.06 ± 69.176
Week 3611.76 ± 84.979-9.44 ± 81.662-6.28 ± 62.772-22.30 ± 51.020-8.75 ± 85.214-37.19 ± 71.372-51.27 ± 29.960-32.59 ± 49.531-9.11 ± 110.289
Week 40-13.29 ± 60.249-18.23 ± 79.0257.25 ± 82.513-21.32 ± 50.6594.24 ± 91.941-40.11 ± 67.991-56.66 ± 33.879-35.92 ± 46.888-1.02 ± 98.096
Week 44-2.42 ± 54.527-5.30 ± 88.418-23.23 ± 56.824-31.88 ± 49.100-15.90 ± 85.382-30.93 ± 71.891-41.44 ± 37.143-32.73 ± 57.357-22.21 ± 80.062
Week 48-14.15 ± 60.660-4.47 ± 95.509-28.27 ± 51.499-21.89 ± 53.0104.97 ± 88.017-39.36 ± 69.672-60.77 ± 35.190-36.32 ± 47.746-34.95 ± 67.833
Week 52-8.10 ± 67.182-7.59 ± 92.868-13.70 ± 44.085-19.98 ± 56.4050.43 ± 85.522-14.22 ± 78.739-59.23 ± 37.434-23.84 ± 50.933-18.16 ± 69.310
SecondaryAbsolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24
Reported as:
Mean · score on a scale
Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)
score on a scale250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 1-0.54 ± 1.096-0.56 ± 0.978-0.49 ± 0.965-0.45 ± 0.908-0.28 ± 1.071
Week 2-0.65 ± 1.316-0.79 ± 1.367-0.73 ± 1.075-0.81 ± 1.224-0.42 ± 1.046
Week 3-0.90 ± 1.619-0.92 ± 1.392-1.05 ± 1.302-0.88 ± 1.478-0.65 ± 1.567
Week 4-.096 ± 1.672-1.25 ± 1.657-1.36 ± 1.443-1.09 ± 1.668-0.77 ± 1.744
Week 5-0.99 ± 1.811-1.38 ± 1.653-1.42 ± 1.591-1.49 ± 1.799-0.83 ± 2.030
Week 6-1.09 ± 1.679-1.35 ± 1.818-1.38 ± 1.666-1.58 ± 2.057-0.94 ± 1.899
Week 7-1.25 ± 1.966-1.54 ± 1.850-1.57 ± 1.710-1.78 ± 2.002-0.78 ± 1.922
Week 8-1.42 ± 2.062-1.50 ± 1.786-1.60 ± 1.816-1.93 ± 2.053-0.80 ± 1.979
Week 9-1.44 ± 2.104-1.52 ± 1.805-1.89 ± 1.885-2.13 ± 2.031-1.00 ± 2.142
Week 10-1.62 ± 2.162-1.67 ± 1.852-1.82 ± 2.082-2.17 ± 2.137-0.97 ± 2.244
Week 11-1.68 ± 2.176-1.67 ± 1.936-2.06 ± 2.091-2.31 ± 2.248-0.93 ± 2.111
Week 12-1.70 ± 2.204-1.65 ± 2.074-1.96 ± 2.107-2.28 ± 2.262-0.79 ± 2.162
Week 13-1.83 ± 2.295-1.87 ± 2.247-2.05 ± 2.164-2.28 ± 2.291-0.72 ± 2.087
Week 14-1.82 ± 2.355-2.02 ± 2.468-2.13 ± 2.308-2.35 ± 2.316-0.58 ± 2.055
Week 15-1.87 ± 2.386-2.08 ± 2.511-2.10 ± 2.290-2.32 ± 2.288-0.57 ± 2.018
Week 16-2.06 ± 2.539-2.09 ± 2.497-2.22 ± 2.275-2.31 ± 2.301-0.54 ± 2.077
Week 17-2.13 ± 2.465-2.18 ± 2.457-2.14 ± 2.368-2.35 ± 2.346-0.61 ± 2.143
Week 18-2.18 ± 2.534-2.21 ± 2.543-2.16 ± 2.307-2.37 ± 2.383-0.55 ± 2.168
Week 19-2.19 ± 2.484-2.22 ± 2.563-2.14 ± 2.291-2.38 ± 2.463-0.75 ± 2.278
Week 20-2.28 ± 2.522-2.19 ± 2.530-2.13 ± 2.360-2.31 ± 2.401-0.67 ± 2.201
Week 21-2.28 ± 2.516-2.23 ± 2.576-2.27 ± 2.352-2.43 ± 2.404-0.76 ± 2.332
Week 22-2.38 ± 2.622-2.29 ± 2.699-2.25 ± 2.438-2.44 ± 2.383-0.73 ± 2.314
Week 23-2.56 ± 2.671-2.27 ± 2.538-2.20 ± 2.529-2.59 ± 2.453-0.61 ± 2.215
Week 24-2.58 ± 2.662-2.30 ± 2.672-2.21 ± 2.616-2.46 ± 2.427-0.55 ± 2.224
SecondaryAbsolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Reported as:
Mean · Score on a scale
Absolute Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)
Score on a scale250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-3.63 ± 2.380-2.83 ± 2.909-4.00 ± 2.711-2.25 ± 2.861-4.34 ± 2.169-2.92 ± 2.539-4.63 ± 1.822-2.82 ± 2.571-1.95 ± 3.083
Week 25-3.83 ± 2.353-2.73 ± 2.973-4.08 ± 2.726-2.42 ± 2.895-4.12 ± 2.413-2.81 ± 2.405-4.92 ± 1.863-2.64 ± 2.577-2.08 ± 3.177
Week 26-3.82 ± 2.442-2.71 ± 2.891-3.75 ± 2.654-2.33 ± 3.096-3.83 ± 2.428-2.56 ± 2.400-4.56 ± 1.903-2.70 ± 2.634-1.93 ± 3.202
Week 27-3.84 ± 2.444-2.58 ± 2.819-3.65 ± 2.619-2.28 ± 2.994-4.09 ± 2.567-2.84 ± 2.467-4.51 ± 1.790-2.57 ± 2.748-2.04 ± 3.351
Week 28-3.86 ± 2.432-2.56 ± 2.892-3.59 ± 2.575-2.29 ± 2.782-4.02 ± 2.525-3.01 ± 2.504-4.38 ± 1.827-2.75 ± 2.753-1.89 ± 3.459
Week 29-3.73 ± 2.612-2.51 ± 2.874-3.81 ± 2.425-1.85 ± 2.733-4.16 ± 2.387-2.99 ± 2.591-4.50 ± 2.035-2.64 ± 2.695-1.81 ± 3.386
Week 30-3.32 ± 2.564-2.78 ± 3.030-3.76 ± 2.394-2.07 ± 2.564-4.44 ± 2.526-2.68 ± 2.490-3.73 ± 2.125-2.59 ± 2.653-1.80 ± 3.445
Week 31-3.41 ± 2.580-2.74 ± 3.213-3.73 ± 2.431-1.71 ± 2.980-4.18 ± 2.428-2.81 ± 2.662-4.02 ± 2.280-2.78 ± 2.691-1.46 ± 3.132
Week 32-3.43 ± 2.607-2.56 ± 3.098-3.13 ± 2.818-1.51 ± 2.736-4.27 ± 2.261-2.86 ± 2.617-4.40 ± 2.170-2.68 ± 2.674-1.54 ± 3.221
Week 33-3.60 ± 2.722-2.49 ± 3.220-3.06 ± 2.755-1.85 ± 2.867-4.32 ± 2.316-2.83 ± 2.579-4.14 ± 1.843-2.66 ± 2.705-1.45 ± 3.332
Week 34-3.49 ± 2.644-2.26 ± 3.114-3.32 ± 2.732-1.30 ± 2.792-4.43 ± 2.297-2.84 ± 2.508-3.97 ± 1.948-2.58 ± 2.665-1.86 ± 3.578
Week 35-3.47 ± 2.712-2.51 ± 3.219-3.09 ± 2.600-1.42 ± 2.685-4.60 ± 2.497-3.01 ± 2.529-4.55 ± 2.055-2.65 ± 2.674-1.86 ± 3.390
Week 36-3.48 ± 2.752-2.47 ± 3.262-2.81 ± 2.693-1.64 ± 2.670-4.67 ± 2.468-2.90 ± 2.527-4.14 ± 1.845-2.39 ± 2.626-1.56 ± 3.318
Week 37-3.44 ± 2.726-2.53 ± 3.244-2.50 ± 2.523-1.85 ± 2.758-4.51 ± 2.429-3.11 ± 2.508-4.49 ± 1.992-2.33 ± 2.564-1.58 ± 3.328
Week 38-3.31 ± 3.182-2.33 ± 3.159-2.06 ± 2.464-1.74 ± 2.803-4.57 ± 2.505-3.16 ± 2.672-4.52 ± 2.046-2.37 ± 2.548-1.64 ± 3.449
Week 39-3.34 ± 3.206-2.35 ± 3.212-2.52 ± 2.462-1.81 ± 2.792-4.24 ± 2.451-3.07 ± 2.548-4.66 ± 2.070-2.27 ± 2.605-1.78 ± 3.350
Week 40-3.29 ± 3.245-2.26 ± 3.208-2.11 ± 2.064-1.74 ± 2.697-4.24 ± 2.419-2.92 ± 2.574-2.98 ± 1.946-2.38 ± 2.659-1.67 ± 3.413
Week 41-3.25 ± 3.188-2.26 ± 3.213-1.82 ± 1.991-1.97 ± 2.774-4.56 ± 2.344-2.67 ± 2.798-3.73 ± 2.142-2.41 ± 2.697-1.64 ± 3.856
Week 42-3.21 ± 3.218-2.28 ± 3.307-2.53 ± 2.603-1.91 ± 2.835-4.67 ± 2.494-2.92 ± 2.876-3.78 ± 2.183-2.24 ± 2.655-2.01 ± 3.719
Week 43-3.30 ± 3.246-2.27 ± 3.158-2.53 ± 2.523-1.74 ± 2.821-4.64 ± 2.864-2.82 ± 2.612-3.70 ± 2.063-2.22 ± 2.736-2.31 ± 3.823
Week 44-3.34 ± 3.276-2.31 ± 3.196-2.37 ± 2.349-1.79 ± 2.690-4.83 ± 2.484-2.81 ± 2.693-3.51 ± 2.084-2.21 ± 2.656-2.01 ± 3.730
Week 45-3.63 ± 3.034-2.41 ± 3.267-1.97 ± 2.110-1.87 ± 2.745-4.68 ± 2.637-2.62 ± 2.636-3.58 ± 1.992-2.23 ± 2.678-1.87 ± 3.752
Week 46-3.29 ± 3.359-2.46 ± 3.219-2.61 ± 2.550-1.84 ± 2.679-4.41 ± 2.864-2.33 ± 2.614-3.78 ± 2.146-2.28 ± 2.713-1.99 ± 4.071
Week 47-3.17 ± 3.283-2.31 ± 3.183-1.95 ± 2.320-1.84 ± 2.796-4.46 ± 2.830-2.30 ± 2.731-3.66 ± 2.139-2.38 ± 2.645-1.78 ± 3.762
Week 48-2.82 ± 3.247-2.43 ± 3.202-2.36 ± 2.366-1.84 ± 2.761-4.64 ± 2.892-2.04 ± 2.636-3.96 ± 2.251-2.31 ± 2.731-2.05 ± 3.716
Week 49-2.80 ± 3.230-2.27 ± 3.139-2.66 ± 2.610-2.02 ± 2.909-4.68 ± 2.893-2.02 ± 2.625-3.65 ± 1.938-2.46 ± 2.847-2.06 ± 3.875
Week 50-2.78 ± 3.223-2.23 ± 3.218-2.44 ± 2.699-1.90 ± 2.913-4.56 ± 2.923-1.87 ± 2.596-3.78 ± 2.092-2.35 ± 2.788-2.16 ± 3.870
Week 51-2.67 ± 3.188-2.42 ± 3.317-2.39 ± 2.399-1.80 ± 2.860-4.64 ± 3.094-1.89 ± 2.692-3.66 ± 2.014-2.40 ± 2.777-2.12 ± 3.883
Week 52-2.70 ± 3.119-2.17 ± 3.152-2.53 ± 2.917-1.84 ± 2.779-4.74 ± 2.909-1.84 ± 2.929-3.86 ± 2.135-2.33 ± 2.811-2.12 ± 3.904
SecondaryPercent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 & 24
Reported as:
Mean · Percentage of change
Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 1)
Percentage of change250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 1-6.26 ± 16.312-7.25 ± 13.575-6.18 ± 13.809-6.05 ± 13.049-3.70 ± 16.432
Week 2-7.50 ± 20.644-10.37 ± 19.307-9.86 ± 14.734-11.20 ± 18.124-5.63 ± 15.340
Week 3-11.08 ± 24.712-12.11 ± 18.977-14.11 ± 17.784-12.08 ± 22.244-7.89 ± 22.004
Week 4-12.16 ± 25.287-16.73 ± 22.997-18.37 ± 19.932-14.95 ± 24.356-9.83 ± 24.266
Week 5-12.58 ± 27.613-18.64 ± 23.725-19.20 ± 21.900-20.17 ± 25.112-10.14 ± 29.071
Week 6-13.73 ± 25.374-17.59 ± 25.814-18.68 ± 22.790-21.29 ± 28.179-12.43 ± 27.184
Week 7-15.89 ± 28.992-20.18 ± 25.476-21.18 ± 23.816-24.03 ± 27.650-10.18 ± 28.308
Week 8-18.41 ± 31.375-19.99 ± 24.992-21.14 ± 24.981-26.10 ± 27.810-10.51 ± 29.803
Week 9-18.83 ± 32.003-20.36 ± 25.407-25.45 ± 24.895-29.18 ± 27.455-13.34 ± 32.225
Week 10-21.19 ± 32.110-22.53 ± 25.815-24.46 ± 28.280-29.43 ± 28.109-12.99 ± 33.194
Week 11-21.93 ± 31.966-22.37 ± 26.321-27.67 ± 28.079-31.26 ± 29.641-12.73 ± 31.638
Week 12-22.59 ± 32.927-22.05 ± 28.445-26.52 ± 28.426-31.23 ± 30.323-10.62 ± 32.707
Week 13-23.88 ± 33.561-24.71 ± 30.761-28.18 ± 29.401-31.36 ± 31.724-10.05 ± 32.122
Week 14-23.87 ± 34.926-26.45 ± 32.870-29.19 ± 30.904-32.57 ± 31.719-7.60 ± 31.351
Week 15-24.40 ± 34.899-27.46 ± 33.838-28.87 ± 31.207-32.01 ± 30.980-6.87 ± 29.583
Week 16-26.85 ± 36.332-27.92 ± 33.619-30.75 ± 30.460-31.97 ± 31.194-6.62 ± 30.591
Week 17-27.81 ± 35.262-29.27 ± 33.331-29.68 ± 31.753-32.60 ± 31.851-7.46 ± 31.529
Week 18-28.78 ± 36.738-29.49 ± 34.514-29.89 ± 31.200-32.50 ± 32.096-6.37 ± 31.752
Week 19-28.98 ± 36.372-29.78 ± 35.087-29.83 ± 31.632-32.77 ± 33.698-9.50 ± 33.411
Week 20-30.61 ± 37.215-29.30 ± 34.365-29.48 ± 32.361-31.85 ± 32.767-8.56 ± 32.725
Week 21-30.40 ± 36.928-29.63 ± 34.869-31.61 ± 32.551-33.20 ± 33.098-9.71 ± 34.201
Week 22-31.81 ± 38.100-30.35 ± 36.881-31.15 ± 33.763-33.28 ± 32.108-9.36 ± 34.161
Week 23-34.26 ± 38.693-30.30 ± 35.236-30.52 ± 35.354-35.25 ± 33.102-7.23 ± 32.486
Week 24-34.70 ± 38.656-30.44 ± 36.696-30.64 ± 36.647-33.26 ± 32.433-6.66 ± 32.550
SecondaryPercent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, & 52
Reported as:
Mean · Percentage of change
Percent Change in Weekly Average of Pruritus Numerical Rating Scale (NRS) From Baseline (Part 2)
Percentage of change250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Week 24-49.61 ± 33.036-38.71 ± 44.259-52.36 ± 33.258-29.76 ± 40.611-56.60 ± 24.568-42.27 ± 36.685-59.49 ± 22.140-38.95 ± 34.963-29.09 ± 44.653
Week 25-52.15 ± 31.579-36.78 ± 45.402-53.26 ± 33.810-31.69 ± 40.647-54.31 ± 29.223-41.26 ± 34.643-63.84 ± 23.417-37.04 ± 36.046-30.81 ± 46.001
Week 26-51.62 ± 32.197-36.84 ± 44.342-48.88 ± 32.071-30.68 ± 42.883-50.31 ± 29.134-38.14 ± 35.393-57.52 ± 22.280-37.71 ± 37.451-28.48 ± 46.252
Week 27-52.09 ± 32.613-35.34 ± 44.056-47.36 ± 30.909-29.42 ± 40.379-53.62 ± 30.255-42.65 ± 36.665-57.00 ± 20.810-35.32 ± 38.963-29.92 ± 48.506
Week 28-52.36 ± 32.642-34.80 ± 45.063-47.19 ± 31.551-30.58 ± 38.398-53.08 ± 30.684-44.86 ± 36.493-56.28 ± 24.247-38.37 ± 38.703-27.74 ± 49.936
Week 29-50.48 ± 35.634-34.13 ± 44.735-50.29 ± 29.286-24.35 ± 38.746-54.93 ± 28.705-44.31 ± 37.579-56.79 ± 23.453-36.46 ± 38.211-26.40 ± 48.994
Week 30-44.79 ± 34.219-37.91 ± 46.288-49.35 ± 28.435-28.00 ± 35.916-58.70 ± 30.600-40.30 ± 37.098-48.05 ± 24.892-36.03 ± 38.742-26.58 ± 49.832
Week 31-46.03 ± 34.355-37.18 ± 49.311-49.01 ± 28.581-21.78 ± 41.439-55.77 ± 30.420-42.26 ± 39.161-52.67 ± 29.311-39.45 ± 38.697-21.51 ± 44.331
Week 32-46.40 ± 35.233-34.68 ± 47.719-40.69 ± 34.523-19.61 ± 37.935-57.32 ± 29.140-42.64 ± 38.113-56.51 ± 27.668-37.63 ± 38.453-22.64 ± 46.122
Week 33-48.66 ± 36.625-33.52 ± 48.881-39.31 ± 33.036-24.61 ± 39.502-57.76 ± 29.406-42.45 ± 38.100-52.89 ± 22.337-37.50 ± 39.368-21.49 ± 48.348
Week 34-47.09 ± 35.098-30.56 ± 48.227-43.33 ± 34.277-17.18 ± 39.855-59.41 ± 29.414-42.96 ± 37.718-50.34 ± 22.937-35.63 ± 37.586-27.22 ± 51.629
Week 35-46.67 ± 36.047-33.99 ± 48.416-40.21 ± 32.239-18.51 ± 37.670-61.70 ± 32.381-44.99 ± 37.080-58.12 ± 24.772-36.74 ± 37.592-27.11 ± 48.897
Week 36-46.63 ± 36.326-33.43 ± 48.720-36.23 ± 33.872-22.43 ± 37.322-62.54 ± 31.831-43.37 ± 37.251-52.78 ± 22.120-33.66 ± 38.520-22.57 ± 47.897
Week 37-45.95 ± 35.161-34.42 ± 48.542-32.60 ± 31.909-25.63 ± 39.489-60.49 ± 31.510-46.52 ± 37.336-58.05 ± 27.565-33.22 ± 38.367-22.63 ± 48.038
Week 38-43.12 ± 42.814-31.62 ± 47.534-26.80 ± 31.244-24.20 ± 40.063-60.83 ± 31.559-47.17 ± 39.147-58.43 ± 27.410-33.72 ± 37.516-24.07 ± 49.645
Week 39-43.54 ± 42.937-31.75 ± 48.313-32.75 ± 31.185-25.49 ± 40.126-56.79 ± 31.763-46.10 ± 38.082-59.36 ± 25.162-32.70 ± 38.945-25.98 ± 48.229
Week 40-42.94 ± 43.748-30.52 ± 48.657-27.37 ± 25.233-24.24 ± 38.972-56.78 ± 31.397-43.62 ± 38.048-38.57 ± 22.074-34.20 ± 39.168-24.22 ± 49.044
Week 41-42.33 ± 43.065-30.85 ± 48.900-22.99 ± 23.218-27.38 ± 39.966-61.18 ± 30.487-39.66 ± 42.054-47.95 ± 26.092-34.51 ± 40.123-24.13 ± 55.219
Week 42-41.68 ± 42.874-30.76 ± 50.332-34.23 ± 35.319-26.33 ± 40.513-62.53 ± 32.149-42.91 ± 42.866-49.33 ± 29.448-32.01 ± 39.405-29.48 ± 53.423
Week 43-42.86 ± 43.495-30.51 ± 48.200-33.86 ± 33.053-23.93 ± 40.455-62.27 ± 36.647-41.66 ± 38.115-48.09 ± 26.148-31.34 ± 41.919-33.70 ± 54.865
Week 44-43.47 ± 44.000-31.71 ± 49.607-31.76 ± 30.960-24.67 ± 37.725-64.61 ± 31.787-42.36 ± 40.085-46.04 ± 28.399-31.28 ± 40.103-29.07 ± 53.672
Week 45-47.27 ± 40.996-33.33 ± 50.319-25.91 ± 26.492-25.91 ± 38.680-61.59 ± 33.745-39.63 ± 39.211-47.19 ± 28.645-31.41 ± 39.716-27.07 ± 54.016
Week 46-42.11 ± 45.119-33.68 ± 49.356-34.27 ± 33.932-25.58 ± 38.019-58.81 ± 35.801-34.77 ± 38.757-49.76 ± 30.190-31.98 ± 39.640-28.89 ± 58.573
Week 47-40.77 ± 44.580-31.88 ± 48.778-25.60 ± 30.211-25.44 ± 39.798-59.01 ± 35.211-33.49 ± 39.386-48.45 ± 30.519-33.71 ± 38.282-25.86 ± 54.094
Week 48-36.53 ± 44.443-33.50 ± 48.912-30.33 ± 30.351-25.04 ± 38.230-61.01 ± 35.650-29.89 ± 38.681-51.75 ± 30.214-33.16 ± 40.239-29.29 ± 53.432
Week 49-36.35 ± 44.233-31.23 ± 48.493-34.64 ± 34.631-28.21 ± 41.352-61.21 ± 35.897-29.37 ± 38.374-48.17 ± 27.760-34.32 ± 41.018-29.80 ± 55.717
Week 50-36.14 ± 44.279-31.62 ± 50.758-32.01 ± 36.290-26.10 ± 40.637-59.59 ± 36.330-27.45 ± 38.441-50.18 ± 30.773-32.86 ± 40.330-31.15 ± 55.571
Week 51-34.31 ± 43.008-34.07 ± 51.575-30.83 ± 31.211-24.47 ± 39.779-60.72 ± 38.664-27.10 ± 39.790-48.66 ± 29.191-33.72 ± 40.790-30.75 ± 55.841
Week 52-35.06 ± 42.961-30.54 ± 49.791-33.29 ± 38.191-25.37 ± 39.165-61.83 ± 35.861-25.94 ± 43.683-50.89 ± 29.752-32.36 ± 40.612-30.50 ± 56.024
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 3 With a Baseline Pruritus NRS ≥ 3 From Baseline (Part 1)

The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

Time frame:
Baseline to weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, & 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Pruritus NRS (Numerical Rating Scale) ≥ 3 With a Baseline Pruritus NRS ≥ 3 From Baseline (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Week 12.61.31.31.31.3
Week 23.96.41.36.32.5
Week 39.16.410.47.66.3
Week 410.414.115.613.97.6
Week 515.615.416.919.011.4
Week 610.419.218.221.512.7
Week 716.923.120.825.311.4
Week 822.117.922.126.615.2
Week 920.819.227.331.613.9
Week 1027.323.128.638.015.2
Week 1126.023.131.236.713.9
Week 1226.020.528.638.016.5
Week 1328.626.929.938.013.9
Week 1435.129.528.640.513.9
Week 1529.928.228.640.510.1
Week 1632.533.329.941.810.1
Week 1732.530.827.338.013.9
Week 1836.433.329.943.012.7
Week 1935.132.133.843.015.2
Week 2033.830.831.236.710.1
Week 2137.732.133.836.715.2
Week 2237.730.833.839.213.9
Week 2341.635.937.743.012.7
Week 2440.330.836.439.211.4
SecondaryIncidence Rate of Loss of EASI 50 (Part 2)

The incidence rate of loss of EASI 50 is calculated for participants who achieved EASI 50 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 50 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 50) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

Time frame:
Week 24 to week 52
Reported as:
Number · Events per patient-year
Incidence Rate of Loss of EASI 50 (Part 2)
Events per patient-year250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Incidence Rate of Loss of EASI 50 (Part 2)00.2720.1880.0890.1650.07100.1930.145
SecondaryIncidence Rate of Loss of EASI 75 (Part 2)

The incidence rate of loss of EASI 75 is calculated for participants who achieved EASI 75 at re-randomization (week 24). The incidence rate is computed as the number of participants losing EASI 75 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of EASI 75) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

Time frame:
Week 24 to week 52
Reported as:
Number · Events per patient-year
Incidence Rate of Loss of EASI 75 (Part 2)
Events per patient-year250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Incidence Rate of Loss of EASI 75 (Part 2)00.5870.3750.4860.3950.4460.3510.5730.646
SecondaryIncidence Rate of Loss of IGA 0/1 (Part 2)

The incidence rate of loss of IGA 0/1 is calculated for participants who achieved IGA 0/1 at re-randomization (week 24). The incidence rate is computed as the number of participants losing IGA 0/1 divided by total follow-up time. The follow-up time is defined as the duration from re-randomization (week 24) to either the first event date (loss of IGA 0/1) or censoring date for participants who had no events. The censoring date is defined as the earliest occurrence of: use of rescue medications and/or selected prohibited medications/ procedures impacting efficacy, or study discontinuation/ completion.

Time frame:
Week 24 to week 68
Reported as:
Number · Events per patient-year
Incidence Rate of Loss of IGA 0/1 (Part 2)
Events per patient-year250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Incidence Rate of Loss of IGA 0/1 (Part 2)1.2671.0390.9811.9301.1541.0451.0961.7900.244
SecondarySerum KY1005 Concentration Assessed Throughout the Study (Part 1)
Time frame:
Baseline and at weeks 1, 2, 4, 8, 12, 16, 17, 20, & 24
Reported as:
Mean · (ug/ml)
Serum KY1005 Concentration Assessed Throughout the Study (Part 1)
(ug/ml)250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)
Baseline0.00 ± 0.0140.00 ± 0.0140.01 ± 0.0740.00 ± 0.000
Week 158.29 ± 24.67430.49 ± 18.52014.18 ± 5.0608.49 ± 3.331
Week 247.56 ± 17.27425.09 ± 9.04113.56 ± 3.8867.57 ± 2.947
Week 438.49 ± 22.53219.00 ± 7.8699.67 ± 3.7285.09 ± 2.176
Week 837.67 ± 15.15732.14 ± 16.50215.07 ± 6.3837.92 ± 3.263
Week 1239.26 ± 33.84734.67 ± 15.19118.12 ± 8.4399.22 ± 4.116
Week 1640.12 ± 28.61038.09 ± 13.53618.39 ± 7.24510.13 ± 4.515
Week 1762.34 ± 28.08164.64 ± 24.16929.26 ± 11.65916.79 ± 6.677
Week 2037.92 ± 14.17148.26 ± 30.69119.31 ± 7.20310.68 ± 3.715
Week 2441.98 ± 23.08743.81 ± 17.40320.25 ± 10.57511.07 ± 3.918
SecondarySerum KY1005 Concentration Assessed Throughout the Study (Part 2)
Time frame:
Baseline and at weeks 24, 25, 28, 32, 36, 40, 44, 48, & 52
Reported as:
Mean · (ug/ml)
Serum KY1005 Concentration Assessed Throughout the Study (Part 2)
(ug/ml)250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)
Week 2445.13 ± 15.84236.68 ± 17.54445.00 ± 14.56843.17 ± 19.75219.03 ± 9.61219.48 ± 7.79111.60 ± 1.38311.10 ± 5.240
Week 2573.54 ± 30.68036.54 ± 20.50871.25 ± 16.29434.71 ± 14.55131.07 ± 16.11517.57 ± 7.50415.90 ± 2.44310.36 ± 5.145
Week 2851.50 ± 25.45417.59 ± 9.09046.15 ± 15.78225.22 ± 10.23520.12 ± 11.82010.03 ± 4.6979.56 ± 3.4856.66 ± 2.584
Week 3244.41 ± 11.4388.86 ± 5.07441.50 ± 13.68112.54 ± 5.94320.99 ± 12.6144.57 ± 2.4639.40 ± 1.7493.32 ± 1.588
Week 3643.11 ± 18.9655.41 ± 3.87651.42 ± 18.9467.80 ± 4.41322.28 ± 18.1012.85 ± 2.27513.38 ± 2.1281.77 ± 1.018
Week 4045.19 ± 19.9212.42 ± 1.66043.79 ± 15.9554.54 ± 2.92919.09 ± 11.4791.68 ± 1.66910.95 ± 1.3500.96 ± 0.748
Week 4440.91 ± 12.0681.04 ± 0.90846.98 ± 24.0152.62 ± 2.19316.43 ± 7.3020.82 ± 0.86311.25 ± 2.6070.57 ± 0.554
Week 4841.43 ± 14.2140.58 ± 0.50743.63 ± 22.1881.40 ± 1.72717.80 ± 9.0650.42 ± 0.48311.12 ± 1.8250.25 ± 0.305
Week 5238.88 ± 11.5260.56 ± 1.11245.59 ± 22.4470.55 ± 0.57322.60 ± 8.2250.19 ± 0.28912.03 ± 3.7750.11 ± 0.129
SecondaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 1)
Time frame:
Baseline through week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)
Any Treatment Emergent Adverse Event66.266.767.567.960.3
Any Serious Treatment Emergent Adverse Event2.601.36.41.3
SecondaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 2)
Time frame:
Week 24 through week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Any Serious TEAE (Part 2)
Percentage of participants250 mg KY1005 Re-randomized From the 250mg (LD) Arm (Part 2)Placebo Re-randomized From the 250mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2) Continued From Part 1 Placebo
Any Treatment Emergent Adverse Event84.667.663.678.666.787.557.167.666.7
Any Serious Treatment Emergent Adverse Event7.72.907.18.30000
SecondaryPercentage of Participants With Treatment-emergent ADA (Part 1)
Time frame:
Baseline through week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent ADA (Part 1)
Percentage of participants250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)
Percentage of Participants With Treatment-emergent ADA (Part 1)2.66.413.232.1
SecondaryPercentage of Participants With Treatment-emergent ADA (Part 2)
Time frame:
Baseline through week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent ADA (Part 2)
Percentage of participants250 mg KY1005 Re-randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg Arm (Part 2)62.5 mg KY1005 Re-randomized From the 62.5 mg Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)
Percentage of Participants With Treatment-emergent ADA (Part 2)7.79.19.119.2035.528.642.4

Adverse events

Collected over Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), all-cause mortality (deaths) were collected from the first dose of study treatment (Day 1) up to the last dose of the study treatment (Day 337)+ 140 days safety follow-up for each participant, up to 477 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
250 mg (500 mg LD) KY1005 (Part 1)0/77 (0%)2/77 (2.6%)42/77 (54.5%)
250 mg (no LD) KY1005 (Part 1)0/78 (0%)0/78 (0%)39/78 (50%)
125 mg KY1005 (Part 1)0/77 (0%)1/77 (1.3%)39/77 (50.6%)
62.5 mg KY1005 (Part 1)0/78 (0%)5/78 (6.4%)41/78 (52.6%)
Placebo (Part 1)0/78 (0%)1/78 (1.3%)41/78 (52.6%)
250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2)0/13 (0%)1/13 (7.7%)11/13 (84.6%)
Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)0/34 (0%)1/34 (2.9%)21/34 (61.8%)
250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)0/11 (0%)0/11 (0%)7/11 (63.6%)
Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)0/28 (0%)2/28 (7.1%)19/28 (67.9%)
125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)0/12 (0%)1/12 (8.3%)8/12 (66.7%)
Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)0/32 (0%)0/32 (0%)27/32 (84.4%)
62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)0/7 (0%)0/7 (0%)4/7 (57.1%)
Placebo Re-randomized From the 62.5 mg Arm (Part 2)0/34 (0%)0/34 (0%)21/34 (61.8%)
Placebo (Part 2)0/15 (0%)0/15 (0%)10/15 (66.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
Event250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2)
Ankle fractureInjury, poisoning and procedural complications0/770/780/770/780/780/130/340/110/281/120/320/70/340/15
Umbilical herniaGastrointestinal disorders0/770/780/770/780/781/130/340/110/280/120/320/70/340/15
Abnormal loss of weightMetabolism and nutrition disorders0/770/780/770/780/780/130/340/111/280/120/320/70/340/15
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/770/780/77—0/780/130/340/111/280/120/320/70/340/15
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/770/780/77—0/780/130/340/111/280/120/320/70/340/15
Tendon ruptureInjury, poisoning and procedural complications0/770/780/770/780/780/131/340/110/280/120/320/70/340/15
Supraventricular tachycardiaCardiac disorders1/770/780/770/780/780/130/340/110/280/120/320/70/340/15
Metabolic acidosisMetabolism and nutrition disorders1/770/780/77—0/780/130/340/110/280/120/320/70/340/15
Tension HeadacheNervous system disorders1/770/780/77—0/780/130/340/110/280/120/320/70/340/15
Alcohol withdrawal syndromePsychiatric disorders1/770/780/77—0/780/130/340/110/280/120/320/70/340/15
Most frequent other events
Showing 10 of 51
Most frequent other events
Event250 mg (500 mg LD) KY1005 (Part 1)250 mg (no LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2)250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2)Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2)125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2)Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2)62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2)Placebo Re-randomized From the 62.5 mg Arm (Part 2)Placebo (Part 2)
DERMATITIS ATOPICSkin and subcutaneous tissue disorders9/7716/7815/7713/7830/786/1314/343/1115/281/1214/321/712/344/15
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/773/782/774/782/780/130/344/110/281/121/320/70/342/15
NASOPHARYNGITISInfections and infestations14/776/789/775/787/782/134/341/112/280/125/320/73/342/15
HEADACHENervous system disorders4/774/784/777/783/782/131/341/111/282/122/320/71/341/15
CYSTITISInfections and infestations0/771/780/770/781/780/130/340/110/280/120/321/70/340/15
URINARY TRACT INFECTIONInfections and infestations0/771/780/770/780/780/131/341/110/280/120/321/70/340/15
MUSCLE STRAINInjury, poisoning and procedural complications0/770/780/770/780/780/130/340/110/280/120/321/70/340/15
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations4/772/780/772/782/780/130/340/110/281/121/321/72/340/15
BACK PAINMusculoskeletal and connective tissue disorders1/770/781/771/782/780/130/340/110/280/122/321/70/340/15
SPINAL PAINMusculoskeletal and connective tissue disorders2/770/780/770/780/780/131/340/110/280/120/320/70/342/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)250 mg (500 mg LD) KY1005 (Part 1)250 mg (No LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)Total
Mean36.3 ± 13.3240.8 ± 15.2437.9 ± 15.1737.6 ± 14.7836.4 ± 13.0737.8 ± 14.36
Sex: Female, Male
Sex: Female, Male(Participants)250 mg (500 mg LD) KY1005 (Part 1)250 mg (No LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)Total
Female3035393730171
Male4743384249219
Race (NIH/OMB)
Race (NIH/OMB)(Participants)250 mg (500 mg LD) KY1005 (Part 1)250 mg (No LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)Total
American Indian or Alaska Native000000
Asian121210141260
Native Hawaiian or Other Pacific Islander000000
Black or African American4244620
White6163636060307
More than one race000000
Unknown or Not Reported010113
EASI Score at Baseline
EASI Score at Baseline(units on a scale)250 mg (500 mg LD) KY1005 (Part 1)250 mg (No LD) KY1005 (Part 1)125 mg KY1005 (Part 1)62.5 mg KY1005 (Part 1)Placebo (Part 1)Total
Mean30.3 ± 11.6628.7 ± 10.5330.3 ± 12.4328.7 ± 10.0926.4 ± 7.8528.9 ± 10.65
08

Study locations

103 sites
  • Investigative Site Number: 1018
    Fremont, California 94538-1601, United States
  • Investigative site #1022
    Sacramento, California 95816-3370, United States
  • Investigative Site Number: 1006
    Boca Raton, Florida 33428, United States
  • Investigative Site Number: 1001
    Clearwater, Florida 33756-3424, United States
  • Investigative Site Number: 1019
    Coral Gables, Florida 33134-2950, United States
  • Investigative Site Number: 1007
    Miami, Florida 33176-2264, United States
  • Investigative Site Number: 1013
    Tampa, Florida 33615-3816, United States
  • Investigative Site Number: 1004
    Savannah, Georgia 31406-2668, United States
  • Investigative Site Number: 1010
    Clarksville, Indiana 47129-2201, United States
  • Investigative Site Number: 1015
    Indianapolis, Indiana 46250-2041, United States
  • Investigative Site Number: 1021
    Louisville, Kentucky 40241, United States
  • Investigative Site Number: 1011
    Towson, Maryland 21204-7448, United States
  • Investigative Site Number: 1014
    Beverly, Massachusetts 01915-1666, United States
  • Investigative Site Number: 1012
    Troy, Michigan 48084-3536, United States
  • Investigative Site Number: 1005
    Tulsa, Oklahoma 74136-7049, United States
  • Investigative Site Number: 1017
    Portland, Oregon 97223-6683, United States
  • Investigative Site Number: 1009
    Portland, Oregon 97239, United States
  • Investigative Site Number: 1003
    Anderson, South Carolina 29621-2062, United States
  • Investigative Site Number: 1008
    Murfreesboro, Tennessee 37130-2450, United States
  • Investigative site #1023
    Mansfield, Texas 76063, United States
  • Investigative Site Number 3002
    Carlton, 3053, Australia
  • Investigative Site Number: 3003
    East Melbourne, 3002, Australia
  • Investigational Site Number: 3001
    Parkville, 3050, Australia
  • Investigative Site Number: 2004
    Pleven, 5800, Bulgaria
  • Investigative Site Number: 2005
    Sofia, 1431, Bulgaria
  • Investigative Site Number: 2006
    Sofia, 1592, Bulgaria
  • Investigative Site Number: 2003
    Sofia, 1612, Bulgaria
  • Investigative Site Number: 2002
    Sofia, 1784, Bulgaria
  • Investigative Site Number: 2001
    Stara Zagora, 6003, Bulgaria
  • Investigative Site Number: 1106
    Markham, Ontario L3P 1X2, Canada
  • Investigative site #1108
    Niagara Falls, Ontario L2H 1H5, Canada
  • Investigative Site Number: 1103
    Ottawa, Ontario K2C 3N2, Canada
  • Investigative Site Number: 1107
    Waterloo, Ontario N2J 1C4, Canada
  • Investigative Site Number: 1101
    Windsor, Ontario N8W 1E6, Canada
  • Investigative Site Number: 2105
    Nový Jicín, Moravian-Silesian Region 741 01, Czechia
  • Investigative Site Number: 2102
    Prague, Praha, Hlavní Mesto 108 00, Czechia
  • Investigative Site Number: 2103
    Prague, Praha, Hlavní Mesto 130 00, Czechia
  • Investigative Site Number: 2108
    Brno, South Moravian 602 00, Czechia
  • Investigative Site Number: 2106
    Kutná Hora, 284 01, Czechia
  • Investigative Site Number: 2104
    Ostrava, 702 00, Czechia
  • Investigative Site Number: 2209
    Erlangen, Bavaria 91054, Germany
  • Investigative Site Number: 2202
    Blankenfelde, Brandenburg 15827, Germany
  • Investigator Site Number: 2201
    Münster, North Rhine-Westphalia 48149, Germany
  • Investigative Site Number: 2208
    Kiel, Schleswig-Holstein 2405, Germany
  • Investigative Site Number: 2203
    Berlin, 10117, Germany
  • Investigative Site Number: 2204
    Hamburg, 20251, Germany
  • Investigative Site Number: 2305
    Gyula, Bekes County 5700, Hungary
  • Investigative Site Number: 2307
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Investigative Site Number: 2301
    Szeged, Csongrád megye 6720, Hungary
  • Investigative Site Number: 2303
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Investigative Site Number: 2306
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Investigative Site Number: 2302
    Zalaegerszeg, Zala County 8900, Hungary
  • Investigative Site Number: 2304
    Budapest, 1036, Hungary
  • Investigative Site Number: 3103
    Matsudo, Chiba 270-2223, Japan
  • Investigative Site Number: 3114
    Obihiro-Shi, Hokkaidô 080-0013, Japan
  • Investigative site #3108
    Kagoshima, Kagoshima-ken 890-0063, Japan
  • Investigative site #3113
    Yokohama, Kanagawa 221-0825, Japan
  • Investigative Site Number: 3112
    Adachi-Ku, Tokyo 120-0034, Japan
  • Investigative Site Number: 3115
    Chuo Ku, Tokyo, Japan
  • Investigative Site Number: 3104
    Edagowa-Ku, Tokyo 133-0052, Japan
  • Investigative Site Number: 3111
    Koto-Ku, Tokyo 136-0074, Japan
  • Investigative Site Number: 3107
    Minato-Ku, Tokyo 108-0014, Japan
  • Investigative site #3105
    Setagaya-Ku, Tokyo 158-0097, Japan
  • Investigative site #3102
    Kyoto, 602-0841, Japan
  • Investigative Site Number: 3106
    Mibu-machi, 321-0293, Japan
  • Investigative site #3101
    Sapporo, 060-0063, Japan
  • Investigative Site Number: 3109
    Habikino-Shi, Ôsaka 583-0872, Japan
  • Investigative Site Number: 3110
    Sakaishi, Ôsaka 593-8324, Japan
  • Investigative Site Number: 2408
    Krakow, Lesser Poland Voivodeship 30-033, Poland
  • Investigative Site Number: 2407
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Investigative Site Number: 2409
    Krakow, Lesser Poland Voivodeship 31-011, Poland
  • Investigative Site Number: 2414
    Wroclaw, Lower Silesian Voivodeship 50-088, Poland
  • Investigative Site Number: 2418
    Wroclaw, Lower Silesian Voivodeship 50-368, Poland
  • Investigative Site Number: 2417
    Wroclaw, Lower Silesian Voivodeship 51-685, Poland
  • Investigative Site Number: 2420
    Lodz, Lódzkie 90-349, Poland
  • Investigative Site Number: 2415
    Lódz, Lódzkie 90-127, Poland
  • Investigative Site Number: 2412
    Warsaw, Masovian Voivodeship 00-874, Poland
  • Investigative Site Number: 2411
    Warsaw, Masovian Voivodeship 01-142, Poland
  • Investigative Site Number: 2413
    Warsaw, Masovian Voivodeship 01-192, Poland
  • Investigative Site Number: 2401
    Rzeszów, Podkarpackie Voivodeship 35-055, Poland
  • Investigative site #2419
    Bialystok, Podlaskie Voivodeship 15-879, Poland
  • Investigative Site Number: 2402
    Gdansk, Pomeranian Voivodeship 80-382, Poland
  • Investigative Site Number: 2404
    Gdynia, Pomeranian Voivodeship 81-384, Poland
  • Investigative Site Number: 2405
    Katowice, Silesian Voivodeship 40-040, Poland
  • Investigative Site Number: 2410
    Szczecin, West Pomeranian Voivodeship 71-434, Poland
  • Investigative site #2419
    Bialystok, 15-879, Poland
  • Investigative Site Number: 2403
    Gdansk, 80-592, Poland
  • Investigative Site Number: 2406
    Krakow, 31-559, Poland
  • Investigative site #2420
    Lodz, 90-349, Poland
  • Investigative Site Number: 2416
    Lodz, Łódź Voivodeship 90-436, Poland
  • Investigative Site Number: 2502
    Manises, Valencia 46940, Spain
  • Investigative Site Number: 2505
    Alicante, 3010, Spain
  • Investigative Site Number: 2501
    Córdoba, 14004, Spain
  • Investigative Site Number: 2503
    Madrid, 28046, Spain
  • Investigative Site Number: 2504
    Pontevedra, 36001, Spain
  • Investigative Site Number: 3201
    Niao Song Qu, 833, Taiwan
  • Investigative Site Number: 3202
    Taichung, 402, Taiwan
  • Investigative site # 3206
    Taipei, 11217, Taiwan
  • Investigative site # 3206
    Taipei, 112217, Taiwan
  • Investigative Site Number: 3203
    Taoyuan, 33305, Taiwan

Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Reich A, Blauvelt A, Weidinger S, Shi VY, Katoh N, Lynde C, Gao X, Armstrong NM, Bernigaud C, Rahawi K. A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study. Dermatol Ther (Heidelb). 2026 Jan;16(1):605-616. doi: 10.1007/s13555-025-01609-6. Epub 2025 Dec 8. PubMed 41359216 ↗
  • Blauvelt A, Chovatiya R, Merola JF, Weidinger S, Igawa K, Brookes E, Weber C, Wang J, Gray C. Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab. J Eur Acad Dermatol Venereol. 2025 Dec;39(12):2113-2120. doi: 10.1111/jdv.20877. Epub 2025 Jul 24. PubMed 40704660 ↗
  • Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, Lynde C, Kataoka Y, Foley P, Wei X, Wong W, Solente AC, Weber C, Adelman S, Davey S, Hurbin F, Rynkiewicz N, Yen K, O'Malley JT, Bernigaud C. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025 Apr;155(4):1264-1275. doi: 10.1016/j.jaci.2024.10.031. Epub 2024 Nov 8. PubMed 39522654 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Supporting information: Study protocol, Statistical analysis plan

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Apr 2023, 16 months.

Results were first posted in Jul 2025, 2 years 2 months after primary completion. A results delay was requested in Apr 2024.

Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 23, 2021
StartActual
Dec 13, 2021
Primary completionActual
Apr 26, 2023
CompletionActual
Feb 21, 2024
Results delay requested
Apr 24, 2024
Results first posted
Jul 3, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05131477
Lead sponsor
Kymab Limited
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Dec 13, 2021
Primary completion
Apr 26, 2023
Completion
Feb 21, 2024
Results posted
Jul 3, 2025
Last update
Jul 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion